



Cochrane
Library

Cochrane Database of Systematic Reviews

Treatment for mitochondrial disorders (Review)

Pfeffer G, Majamaa K, Turnbull DM, Thorburn D, Chinnery PF

Pfeffer G, Majamaa K, Turnbull DM, Thorburn D, Chinnery PF.
Treatment for mitochondrial disorders.
Cochrane Database of Systematic Reviews 2012, Issue 4. Art. No.: CD004426.
DOI: [10.1002/14651858.CD004426.pub3](https://doi.org/10.1002/14651858.CD004426.pub3).

www.cochranelibrary.com

TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
BACKGROUND	4
OBJECTIVES	5
METHODS	6
RESULTS	7
Figure 1.	8
DISCUSSION	11
AUTHORS' CONCLUSIONS	13
ACKNOWLEDGEMENTS	13
REFERENCES	14
CHARACTERISTICS OF STUDIES	18
ADDITIONAL TABLES	29
APPENDICES	32
WHAT'S NEW	35
HISTORY	35
CONTRIBUTIONS OF AUTHORS	35
DECLARATIONS OF INTEREST	35
SOURCES OF SUPPORT	35
DIFFERENCES BETWEEN PROTOCOL AND REVIEW	36
INDEX TERMS	36

[Intervention Review]

Treatment for mitochondrial disorders

Gerald Pfeffer^{1,2}, Kari Majamaa³, Douglass M Turnbull⁴, David Thorburn⁵, Patrick F Chinnery¹

¹Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK. ²Clinician Investigator Program, University of British Columbia, Vancouver, Canada. ³Institute of Clinical Medicine, Department of Neurology, University of Oulu, Oulu, Finland. ⁴Mitochondrial Research Group, The Medical School, Newcastle University, Newcastle Upon Tyne, UK. ⁵Murdoch Children's Research Institute, Royal Children's Hospital, Victoria, Australia

Contact address: Patrick F Chinnery, Institute of Genetic Medicine, Newcastle University, Central Parkway, Newcastle upon Tyne, NE1 3BZ, UK. p.f.chinnery@ncl.ac.uk.

Editorial group: Cochrane Neuromuscular Group.

Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 4, 2012.

Citation: Pfeffer G, Majamaa K, Turnbull DM, Thorburn D, Chinnery PF. Treatment for mitochondrial disorders. *Cochrane Database of Systematic Reviews* 2012, Issue 4. Art. No.: CD004426. DOI: [10.1002/14651858.CD004426.pub3](https://doi.org/10.1002/14651858.CD004426.pub3).

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Mitochondrial respiratory chain disorders are the most prevalent group of inherited neurometabolic diseases. They present with central and peripheral neurological features usually in association with other organ involvement including the eye, the heart, the liver, and kidneys, diabetes mellitus and sensorineural deafness. Current treatment is largely supportive and the disorders progress relentlessly causing significant morbidity and premature death. Vitamin supplements, pharmacological agents and exercise therapy have been used in isolated cases and small clinical trials, but the efficacy of these interventions is unclear. The first review was carried out in 2003, and identified six clinical trials. This major update was carried out to identify new studies and grade the original studies for potential bias in accordance with revised Cochrane Collaboration guidelines.

Objectives

To determine whether there is objective evidence to support the use of current treatments for mitochondrial disease.

Search methods

We searched the Cochrane Neuromuscular Disease Group Specialized Register (4 July 2011), CENTRAL (2011, Issue 2, MEDLINE (1966 to July 2011), and EMBASE (January 1980 to July 2011), and contacted experts in the field.

Selection criteria

We included randomised controlled trials (including cross-over studies). Two of the authors independently selected abstracts for further detailed review. Further review was performed independently by all five authors to decide which trials fit the inclusion criteria and graded risk of bias. Participants included males and females of any age with a confirmed diagnosis of mitochondrial disease based upon muscle histochemistry, respiratory chain complex analysis of tissues or cell lines or DNA studies. Interventions included any pharmacological agent, dietary modification, nutritional supplement, exercise therapy or other treatment. The review authors excluded studies at high risk of bias in any category. The primary outcome measures included an change in muscle strength and/or endurance, or neurological clinical features. Secondary outcome measures included quality of life assessments, biochemical markers of disease and negative outcomes.

Data collection and analysis

Two of the authors (GP and PFC) independently identified studies for further evaluation from all abstracts within the search period. For those studies identified for further review, all five authors then independently assessed which studies met the entry criteria. For the included studies, we extracted details of the number of randomised participants, treatment, study design, study category, allocation

concealment and other risk of bias criteria, and participant characteristics. Analysis was based on intention-to-treat data. We planned to use meta-analysis, but this did not prove necessary.

Main results

The authors reviewed 1335 abstracts, and from these identified 21 potentially eligible abstracts. Upon detailed review, 12 studies fulfilled the entry criteria. Of these, eight were new studies that had been published since the previous version of this review. Two studies which were included in the previous version of this review were excluded because of potential for bias. The comparability of the included studies is extremely low because of differences in the specific diseases studied, differences in the therapeutic agents used, dosage, study design, and outcomes. The methodological quality of included studies was generally high, although risk of bias was unclear in random sequence generation and allocation concealment for most studies. Otherwise, the risk of bias was low for most studies in the other categories. Serious adverse events were uncommon, except for peripheral nerve toxicity in a long-term trial of dichloroacetate (DCA) in adults.

One trial studied high-dose coenzyme Q10 without clinically meaningful improvement (although there were multiple biochemical, physiologic, and neuroimaging outcomes, in 30 participants). Three trials used creatine monohydrate alone, with one reporting evidence of improved measures of muscle strength and post-exercise lactate, but the other two reported no benefit (total of 38 participants). One trial studied the effects of a combination of coenzyme Q10, creatine monohydrate, and lipoic acid and reported a statistically significant improvement in biochemical markers and peak ankle dorsiflexion strength, but overall no clinical improvement in 16 participants. Five trials studied the effects of DCA: three trials in children showed a statistically significant improvement in secondary outcome measures of mitochondrial metabolism (venous lactate in three trials, and magnetic resonance spectroscopy (MRS) in one trial; total of 63 participants). One trial of short-term DCA in adults demonstrated no clinically relevant improvement (improved venous lactate but no change in physiologic, imaging, or questionnaire findings, in eight participants). One longer-term DCA trial in adults was terminated prematurely due to peripheral nerve toxicity without clinical benefit (assessments included the GATE score, venous lactate and MRS, in 30 participants). One trial using dimethylglycine showed no significant effect (measurements of venous lactate and oxygen consumption (VO₂) in five participants). One trial using a whey-based supplement showed statistically significant improvement in markers of free radical reducing capacity but no clinical benefit (assessments included the Short Form 36 Health Survey (SF-36) questionnaire and UK Medical Research Council (MRC) muscle strength, in 13 participants).

Authors' conclusions

Despite identifying eight new trials there is currently no clear evidence supporting the use of any intervention in mitochondrial disorders. Further research is needed to establish the role of a wide range of therapeutic approaches. We suggest further research should identify novel agents to be tested in homogeneous study populations with clinically relevant primary endpoints.

PLAIN LANGUAGE SUMMARY

Treatment for mitochondrial disorders

Mitochondria are found within every human cell and are responsible for the majority of each cell's energy production. When the mitochondria do not function properly, they cause diseases affecting many of the body's organs. Usually, these are the organs with the highest energy needs, such as muscle, brain, the eyes, and heart, although these diseases are highly variable. As a group these conditions are referred to as mitochondrial disorders, and they can cause significant disability or early death. We conducted this review of treatment for mitochondrial disorders to determine whether any available treatments are effective. We identified 12 randomised controlled trials that were of high enough quality to be included in the review. Of these, eight were new studies that had been published since the previous version of this review. Two studies which were included in the previous version of this review were excluded because of a high risk that the study results may be biased.

The included studies are not easily comparable because of differences in the treatment being studied, the dosage of these treatments, the length of study (and other differences in the study methods), and differences in the types of participants included for the research. The studies were generally well designed in order to reduce the possibility of bias, although for most studies the methods describing how participants were randomised were not described in detail. Otherwise, the risk of bias was low for most studies in the other categories. Serious side effects of treatment were uncommon, except for nerve damage in a long-term trial of dichloroacetate in adults.

One trial studied high-dose coenzyme Q10 treatment. This treatment had no clinical benefit. Three trials used creatine monohydrate: one trial reported improved muscle strength and biochemical measurements, but the other two trials reported no benefit (total of 38 participants). One trial studied the effects of a combination of coenzyme Q10, creatine monohydrate and lipoic acid, and reported a statistically significant improvement in biochemical measurements and ankle strength, but no clinical improvement (16 participants). Five trials studied the effects of dichloroacetate: three trials in children showed a statistically significant improvement in biochemical measurements but no clinical benefit on physiological measurements and exercise tests (total 63 participants); one trial of short-term therapy in adults demonstrated no clinical improvement in physiological measurements (total eight participants), and one longer-term trial in adults was terminated prematurely due to adverse effects without clinical benefit (using a combined scale of treatment effect, in 30 participants). One trial using dimethylglycine showed no significant effect on biochemical markers in five participants. One trial using a whey-based supplement demonstrated statistically significant improvement in biochemical markers but no clinical benefit in muscle strength or on health questionnaires (13 participants).

Treatment for mitochondrial disorders (Review)

Further randomised controlled trials of high quality are needed. They should strictly address outcomes which are relevant to patient care and quality of life, and study these in particular subtypes of mitochondrial disease at a time. The current repertoire of nutritional supplements have been not shown to be effective and future trials should study new treatments.

BACKGROUND

General introduction

Mitochondria are responsible for converting food into energy within human cells. There are a number of genetically determined abnormalities of mitochondria that cause human diseases. These diseases usually involve organs that are heavily dependent upon the energy produced by mitochondria such as the brain, peripheral nerves, limb muscles, heart and hormone-producing glands. As a result, mitochondrial disorders can cause muscle weakness on its own, but this is often associated with neurological, heart and hormone problems including diabetes. There is currently no established treatment for mitochondrial disorders, but there have been a number of case reports and small trials describing the positive effects of a number of different drugs, vitamins and food supplements. Exercise therapy has also been shown to help with the muscle symptoms. The purpose of this review was to assess objectively the available evidence for the various treatments that have been tried in mitochondrial myopathy and mitochondrial encephalomyopathy. Leber hereditary optic neuropathy (LHON) is also a primary mitochondrial disorder that usually just affects the eye. This disease has also been included in this study.

Mitochondria and human disease

Mitochondrial disorders are a diverse group of conditions that often involve the nervous system, are usually progressive, and often cause significant disability and premature death (Schapira 2006; DiMauro 2003). Based upon recent epidemiological studies, mitochondrial disorders affect at least 1 in 8000 of the general population (Schaefer 2008).

Mitochondrial function and biogenesis

Mitochondria are complex ubiquitous intracellular organelles that perform an essential role in a number of cellular processes (Wallace 1999). They contain enzymes involved in cellular metabolism, and are involved in many cell death pathways. It is therefore possible that mitochondria play a central role in many disease processes. Mitochondria also play a pivotal role in the final common pathway of aerobic metabolism - oxidative phosphorylation (OXPHOS). Oxidative phosphorylation is carried out by the mitochondrial respiratory chain, which is a group of five multi-subunit enzyme complexes situated on the inner mitochondrial membrane that generate adenosine triphosphate (ATP) from intermediary metabolites. Adenosine triphosphate is a high-energy phosphate molecule that provides an energy source for all active cellular processes. The term 'mitochondrial disorders' usually refers to primary disorders of the mitochondrial respiratory chain.

Molecular pathology of mitochondrial disorders

The respiratory chain has a dual genetic basis (DiMauro 1998). The vast majority of the respiratory chain subunits (more than 70) are the products of nuclear genes. These subunits are synthesised within the cytosol and are delivered into mitochondria by a peptide targeting sequence. By contrast, 13 essential respiratory chain subunits are synthesised within the mitochondrial matrix from small 16.5 kb circles of double-stranded DNA called mitochondrial DNA (mtDNA) (Anderson 1981). MtDNA is different to nuclear DNA in a number of respects. First, there are many thousands of copies of mtDNA within each cell. MtDNA mutations may only affect a proportion of the mtDNA molecules, leading to a mixture

of mutant and wild-type mtDNA within the cell (heteroplasmy) (Holt 1988). Single cell studies have shown that the proportion of mutant mtDNA must exceed a critical threshold level before the cell expresses a biochemical defect of the mitochondrial respiratory chain (Schon 1997). This threshold varies from tissue to tissue, and partly explains the tissue-selectivity seen in mitochondrial disorders (Wallace 1994). The percentage level of mutant mtDNA can also vary between and within individuals harbouring a pathogenic mtDNA defect, and this partly explains the clinical variability that is a hallmark of mtDNA disorders (Macmillan 1993). In the last decade it has become clear that nuclear gene defects are a major cause of mitochondrial disease, affecting the assembly and structure of the respiratory chain protein complexes or other components of the respiratory chain, such as coenzyme Q10. Nuclear gene defects can also affect the maintenance of mtDNA, leading to secondary mitochondrial DNA mutations which accumulate during life; or they can affect the translation of the mitochondrial genome itself (Spinazzola 2009). Some of these disorders have a distinct clinical phenotype, but others cause an overlapping spectrum of phenotypes similar to primary disorders of mtDNA (Zhu 2009).

Clinical features of mitochondrial diseases

Mitochondrial disorders principally affect tissues that are heavily dependent upon oxidative metabolism. These tissues include the central nervous system, peripheral nerves, eye, skeletal and cardiac muscle, and endocrine organs. Many individuals with mitochondrial diseases have a multi-system disorder that often involves skeletal muscle and the central nervous system, but some individuals have a disorder that only affects one organ system (DiMauro 2001; Leonard 2000). In general terms, the clinical features of mitochondrial disease can be divided into two groups: central neurological features (including encephalopathy, stroke-like episodes, seizures, dementia and ataxia), and peripheral neurological features (including myopathy, ophthalmoplegia, and peripheral neuropathy). Some individuals have a mixture of central and peripheral features, whereas others have a pure central or peripheral phenotype.

Many individuals with mitochondrial disease have a clearly defined clinical phenotype (summarised in Table 1: Clinical syndromes associated with mitochondrial disease). Chronic progressive external ophthalmoplegia (CPEO), the Kearns-Sayre syndrome (KSS) and Pearson syndrome are usually due to a deletion of mtDNA (Moraes 1989; Zeviani 1988). Leber hereditary optic neuropathy (LHON), mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS), myoclonic epilepsy with ragged-red fibres (MERRF), maternally inherited diabetes and deafness (MIDD), and neurogenic (or neuropathy) ataxia with retinitis pigmentosa (NARP) are usually due to point mutations of mtDNA (Lamantea 2002). Unlike nuclear DNA, mtDNA is inherited down the maternal line, so these disorders either affect sporadic cases or they are passed from mother to child (Chinnery 1998). Children presenting with a relapsing encephalopathy with prominent brain stem signs and lactic acidosis (Leigh syndrome) may have a mtDNA defect, or an underlying nuclear genetic defect causing a respiratory chain deficiency. These mutations can affect the genes that code for the subunits themselves (complexes I and II), genes important for the assembly of an intact respiratory chain (complexes III and IV), or genes involved in mitochondrial transcription or translation, and they are usually autosomal

Treatment for mitochondrial disorders (Review)

recessive (Tucker 2010). Mutations in the gene LPPRC cause a specific form of infantile COX deficiency found in the Saguenay-Lac-Saint-Jean region of Canada (Mootha 2003).

A further group of mitochondrial disorders have recently been defined at the molecular level. These disorders result from a disorder of mtDNA maintenance. For some of these diseases the primary defect is an abnormality of the intra-mitochondrial nucleoside pool. Most individuals with autosomal dominant PEO have a mutation in one of three genes: *PEO1*, *ANT1* or *POLG*, which lead to the formation of multiple mtDNA deletions in muscle (Kaukonen 2000; Spelbrink 2001; Van Goethem 2001). Children presenting with mtDNA depletion syndrome may have mutations in the nuclear genes thymidine kinase 2 (*TK2*) in the myopathic form, or deoxyguanosine kinase (*DGUOK*) or *POLG* in the hepatic form (Mandel 2001; Naviaux 2004; Saada 2001). Secondary mtDNA multiple deletions are also a feature of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) which is also due to a disturbance of the intra-mitochondrial nucleoside pool secondary to thymidine phosphorylase (TP) deficiency (Nishino 1999). A final important group are the disorders associated with coenzyme Q10 (ubiquinone) deficiency. This may present with childhood encephalopathy and seizures, recurrent rhabdomyolysis or ataxia with seizures. Case reports suggest that this disorder responds to Q10 replacement therapy (Musumeci 2001).

A large proportion of individuals with mitochondrial disease do not have a clearly defined phenotype. There may be single or multi-organ involvement including the heart, endocrine organs (particularly the pancreas) and the nervous system. Gastrointestinal complications are an under-recognised but common feature of mitochondrial disorders. Mitochondrial disease should be considered in any patient presenting with an unexplained progressive multi-system disorder with prominent neurological features (Chinnery 1997).

Secondary mitochondrial disorders

Secondary mitochondrial disorders will not be covered in this Cochrane review. Many genetic disorders are associated with abnormal mitochondrial function either as a secondary phenomenon, or because mitochondria play a crucial role in the pathophysiology of the disorder. To date these include three X-linked conditions (Barth syndrome, sideroblastic anaemia with ataxia, deafness and dystonia) and a number of autosomal recessive (Friedreich ataxia, spastic paraparesis SPG4 and SPG13, Wilson disease) and autosomal dominant conditions (hereditary paragangliomas). Increasingly, common neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease are beginning to enter this category as well. Disorders of mitochondrial fusion and fission also result in secondary mitochondrial dysfunction (Westermann 2010). Practically speaking, diseases caused by OPA1 mutation would likely have been covered in this review (autosomal dominant optic atrophy and progressive external ophthalmoplegia), on account of their highly similar clinical presentation with primary mitochondrial disorders. Other fusion/fission defects causing secondary mitochondrial dysfunction (hereditary motor and sensory neuropathy type 2a due to MFN2 mutation, and various other neurological diseases which involve fusion/fission defects in their pathogenesis) have not been included.

The clinical management of mitochondrial disease

There is currently no established treatment for mitochondrial disorders, and the clinical management of individuals is largely supportive. The aims are to provide prognostic information and genetic counselling.

Treatments used to modify the underlying disease process fall into three groups: pharmacological and nutritional agents, modification of macronutrient composition in the diet (dietary supplementation with vitamins and co-factors), and exercise therapy. A number of different pharmacological treatments and nutritional supplements have been used in individuals with mitochondrial disease, with varying reports of success. These include antioxidants (coenzyme Q10, idebenone, vitamin C, vitamin E and menadione), agents that specifically improve lactic acidosis (dichloroacetate and dimethylglycine, which is a component of pangamic acid (vitamin B15)), agents that correct secondary biochemical deficiencies (carnitine, creatine), respiratory chain co-factors (nicotinamide, thiamine, riboflavin, succinate, and coenzyme Q10), and hormones (growth hormone and corticosteroids) (reviewed in Chinnery 2001). Much of the evidence used to support specific treatments comes from single case reports, but there have been a number of small quasi-randomised trials and open-labelled case series. Improvements following dietary modification (for example, a ketogenic diet) and exercise therapy (for example, endurance training) have also been documented in individual cases, and open-labelled trials (Taivassalo 2001). These reports suggest that there might be benefits from these treatments.

To our knowledge this is the only systematic review of clinical trials in mitochondrial disease.

Novel treatment strategies

A number of groups are developing treatments that act on the genetic or cellular level, but it is unlikely that these will be available for individuals in the near future (for review see Hassani 2010).

The aim of this review is to critically appraise the available evidence from RCTs for currently available treatments for individuals with mitochondrial disorders with peripheral neurological features. Our initial protocol for the first review subdivided mitochondrial disorders into encephalopathies and myopathies. After completing the first review, we amalgamated our results into a single report because (a) only a small number of studies were identified, (b) the majority of participants in these studies had both central neurological and neuromuscular features which were both assessed in the same trial. We used the same approach in this revision (completed in 2012).

OBJECTIVES

This review will focus on the treatment of all primary mitochondrial disorders, including specific syndromes, complex multi-system disorders and specific phenotypes such as LHON.

The objective of this review is to examine the effects of pharmacological treatments, and non-pharmacological treatments (vitamins and food supplements), and physical training in improving the symptoms, signs, disability and quality of life in individuals with mitochondrial disorders.

METHODS

Criteria for considering studies for this review

Types of studies

We included RCTs (including cross-over studies). We decided to change our protocol when we updated the review in 2012, and excluded quasi-RCTs (trials in which randomisation is intended but which might be flawed, such as alternate allocation) and RCTs at high risk of bias in any category, since such trials might have results that are not valid.

Types of participants

We included participants of any age with a confirmed diagnosis of mitochondrial disease based upon muscle histochemistry and/or respiratory chain complex analysis of tissues or cell lines and/or DNA studies in mitochondrial DNA or relevant nuclear genes.

Types of interventions

We included any pharmacological agent, dietary modification, nutritional supplement, exercise therapy or other treatment. We did not study the effects of treatments for the complications of mitochondrial disorders (such as ptosis surgery, or cardiac pacing).

Types of outcome measures

Primary outcomes

The primary outcome measures included an change in muscle strength and/or endurance (including the UK Medical Research Council (MRC) muscle strength scale, isometric dynamometer, custom made strain device, vital capacity or maximal voluntary inspiratory or expiratory capacity, or walking speed). For central neurological features, our primary end points were an alteration in a system-specific neurological function score, a reduction of paroxysmal events (such as seizures or stroke-like episodes), visual acuity, pure tone audiometry or cognitive performance. We chose a number of outcome measures because a preliminary literature search identified only a few studies, and each one incorporated different outcome measures. Focussing on one outcome measure would severely limit the scope of this review for a group of disorders with such a complex clinical phenotype. We intended to identify treatment effect at three months after initiation of treatment. This did not prove to be possible, and ultimately we did not choose a specific time point for the primary outcomes. This is because a specific time point would exclude most of the identified studies, as no universal time point has been agreed upon for the assessment of treatments in these disorders.

Secondary outcomes

Secondary outcome measures were as follows.

1. An alteration in quality of life as measured by a recognised scale.
2. Biochemical markers of disease (normalisation of plasma lactate/pyruvate ratio, lowered Vmax as measured by magnetic resonance spectroscopy).
3. Negative outcomes. These included all adverse events attributable to the treatment. Serious adverse events, namely disabling or life-threatening complications, complications which require hospitalisation, and death were recorded separately. A record was made if it was not possible to determine

whether the negative outcome was a consequence of the treatment or part of the natural history of the disease.

If it had been possible to produce a 'Summary of findings' table, we would have selected outcomes that included change in MRC muscle strength, change in quality of life scores, and change in activity of daily living scores. We would also have considered adverse events among the outcomes, including peripheral neuropathy, somnolence, nausea, and hospitalisation. Again, the heterogeneity of these conditions makes the selection of these outcomes extremely difficult, and potentially with limited comparability between studies.

Search methods for identification of studies

We searched the Cochrane Neuromuscular Disease Group Specialized Register (4 July 2011) using the terms 'mitochondrial disease' or 'mitochondrial myopathy' or 'mitochondrial disorder' or 'Disorders of mitochondrial function', or 'chronic progressive external ophthalmoplegia' or 'CPEO' or 'Kearns syndrome' or 'KSS' or 'Kearns Sayre syndrome' or 'Pearson syndrome' or 'Leber hereditary optic neuropathy' or 'LHON' or 'MELAS syndrome' or 'MERRF syndrome' or 'MIDD' or 'NARP' or 'Leigh syndrome' or 'MNGIE'. We adapted this strategy to search the Cochrane Central Register of Controlled Trials (CENTRAL) (2011, Issue 2), MEDLINE (January 1966 to July 2011), EMBASE (January 1980 to July 2011). We searched for RCTs and quasi-RCTs for possible inclusion in the analysis. We also searched for informative single case reports and observational studies, and incorporated these in the discussion. Wherever possible we contacted the authors of these studies for long-term follow up on the individual cases. We also planned to include any unpublished studies conducted by experts in the field by contacting the authors of all published studies and other experts in the field.

The search strategies for MEDLINE, EMBASE and The Cochrane Central Register of Controlled Trials (CENTRAL) are in [Appendix 1](#), [Appendix 2](#) and [Appendix 3](#) respectively.

Data collection and analysis

GP and PFC independently checked titles and abstracts identified using the search strategy, and identified 21 studies for further review. All five authors then independently decided which of these 21 trials fit the inclusion criteria and graded risk of bias according to the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011). Specifically, the bias assessment addressed the following domains: (1) Random sequence generation (method used to randomise participants), (2) Allocation concealment (how randomisation was performed), (3) Blinding of participants and personnel, (4) Blinding of outcome data, (5) Incomplete outcome data, (6) Selective outcome reporting, and (7) Other. For each category, the risk of bias was graded as "Low risk", "High risk", or "Unclear risk" based upon the criteria outlined in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011).

In the original review (2003), four authors (PFC, KM, DMT, DT) performed data extraction and it was concordant in each case. GP and PFC performed data extraction for the 2011 update. We obtained missing data from the trial authors wherever possible. If there had been adequate data we planned to carry out a meta-analysis using mean differences to analyse continuous data and risk ratios to analyse dichotomous data. If data were available for more

than one trial with a specific intervention, we planned to use the Cochrane statistical software Review Manager 5 (RevMan) software using a fixed-effect model. If there was heterogeneity we planned to explore possible reasons for differences between studies such as type of participants, intervention or quality, and we planned to perform sensitivity analyses by omitting trials which lacked one or more of the methodological attributes. We planned to express uncertainty as 95% confidence intervals (CI).

RESULTS

Description of studies

The review authors scanned 1335 abstracts and identified 21 studies for further review, from which the authors selected 12 for inclusion in the review. These studies evaluated the following treatments: coenzyme Q10, creatine, a combination (including creatine, coenzyme Q10 and lipoic acid), dichloroacetate (DCA), dimethylglycine (DMG), or a whey-based cysteine supplement. Nine

studies were excluded, and the reasons for their exclusion have been summarised in [Characteristics of excluded studies](#). The most common reasons for exclusion of these studies was the lack of randomisation ([Bresolin 1990](#); [Muller 1990](#); [DeStefano 1995](#)) and/or blinding ([Suzuki 1998](#); [Cejudo 2005](#); [Koga 2005](#); [Taivassalo 2006](#); [Stacpoole 2008](#)) in most of these studies, which would have a high risk of biasing the results. Other methodological issues which produced a high risk of bias were present in two studies ([Bresolin 1990](#); [Chen 1997](#)). Two of these studies were in abstract format only and could not be adequately assessed ([Muller 1990](#); [Gimenes 2007](#)).

Risk of bias in included studies

See [Characteristics of included studies](#) for 'Risk of bias' ratings for the included studies and [Figure 1](#) for a summary of 'Risk of bias' assessments. The majority of studies included only a small number of participants. Given the various treatments studied, limited size of these studies, the heterogeneous patient groups, and the different end points, we elected not to perform meta-analysis.

Figure 1. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)
DeStefano 1995	?	?	?	+	+	+	+
Duncan 2004	?	?	+	+	+	+	+
Glover 2010	?	?	+	+	?	+	+
Kaufmann 2006	+	+	+	+	+	+	+
Klopstock 2000	?	?	+	+	+	+	+
Kornblum 2005	+	+	+	+	+	+	+
Liet 2003	+	?	+	+	+	+	+
Mancuso 2010	?	?	+	+	?	?	+
Rodriguez 2007	?	?	+	+	+	+	+
Stacpoole 2006	?	?	+	+	+	+	+
Tarnopolsky 1997	?	?	+	+	+	+	+
Vissing 2001	?	?	+	+	+	+	+

Effects of interventions

All 12 studies involved an oral agent (either a pharmacological agent, or a food supplement). The studies are reported in alphabetical order according to the treatment used.

Coenzyme Q10

Glover et al (Glover 2010) studied the effects of high-dose coenzyme Q10 on 30 participants with mitochondrial disease, including 15 with mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS), 11 with progressive external ophthalmoplegia (PEO), two with ataxia-neuropathy syndromes, one with complex I deficiency, and one with Leber hereditary optic neuropathy (LHON). Participants received coenzyme Q10 600 mg orally twice daily for 60 days and placebo for 60

days, with an intervening washout period of 67 +/- 8.3 days. This was a randomised, placebo-controlled, cross-over trial. Outcome assessments were performed at the end of each trial period. These included urine analysis of 8-isoprostane and 8-hydroxy-2-deoxyguanosine. Blood analysis was performed for lactate, glucose, PCO₂, coenzyme Q10, bilirubin, creatine kinase and gamma-glutamyltransferase. Questionnaires were given for quality of life and activities of daily living. Maximal isometric force and near-infrared spectroscopy was measured during a 90 s forearm ischaemic exercise test, with venous lactate, PCO₂, PO₂ at 1 min and 3 min post-test. Dual-energy X-ray absorptometry was performed for body composition. Testing during 15 min cycle ergometry (0 W for 5 min and 30 W for 10 min) monitored heart rate, inspired O₂, expired CO₂, VO₂ and VCO₂ measured at several time points. Venous lactate was measured prior, and at various

points during and after testing. Magnetic resonance spectroscopy (MRS) of cerebrospinal fluid (CSF) lactate, N-acetylaspartate and choline was completed. Statistical analysis included paired t-tests for all measurements. The exception was handgrip PO₂ and PCO₂, which was analysed using two-way repeated measures analysis of variance with Tukey's post hoc test. P values of less than 0.05 were considered to be statistically significant. Results included a statistically significantly increased coenzyme Q10 level. Lactate was statistically significantly decreased at 1 min of cycle ergometry, but there was no difference at other time points. All other endpoints did not differ significantly.

Creatine

Tarnopolsky et al (Tarnopolsky 1997) studied the effects of creatine monohydrate on seven patients with mitochondrial disease, including six with MELAS and one with a mitochondrial myopathy. In this randomised cross-over study, participants received placebo in one period, and in the treatment period received 5 g creatine twice daily for two weeks followed by 2 g twice daily for one week (although measurements were performed at the end of the treatment period, i.e. after three weeks). Measurements included activities of daily living on a visual analogue scale, ischaemic isometric handgrip strength for 1 min, evoked and voluntary contraction strength of dorsiflexor muscles using a dynamometer, nonischaemic isometric dorsiflexion torque for 2 min (NIDFT), and aerobic cycle ergometry (15 to 30 W for 5 to 10 min) with basal and post-ischaemic lactate measurements. Statistical analysis included two-way repeated measures analysis of variance with Tukey's post hoc test for all outcomes (except for body composition variables which used paired t-tests). P values of less than 0.05 were considered to be statistically significant. Creatine resulted in statistically significantly increased handgrip strength (19% increase in torque in N m, $P < 0.01$), NIDFT (11%, $P < 0.01$) and post-exercise lactate ($P < 0.05$) compared with values after treatment with placebo (although we note that these data are represented graphically, with no reported SD, and it is unclear whether mean percentage difference or percentage difference of the means are reported). There was no change in the other variables. No side-effects were noted.

Klopstock et al (Klopstock 2000) studied the effects of creatine monohydrate in 13 participants with PEO and three with mitochondrial myopathy in a randomised placebo controlled cross-over trial. Participants received either 20 g of creatine/day or placebo for four weeks. Measurements included visual analogue scales of subjective weakness and general activity, testing muscle strength in 32 muscles according to the Medical Research Council (MRC) scale, the Hammersmith motor ability score, a neuromuscular symptom score, a function time test, a function ranking test and an ataxia score. Resting and post-exercise lactate was determined following cycle ergometry, and maximal voluntary muscle torque was measured for elbow flexion (biceps at 90°) and knee extension (quadriceps at 110°) using the multifunctional training machine. Aerobic exercise was tested by nonischaemic isokinetic biceps flexion and knee extension (at a speed of 80 °/s with 15% of maximal muscle force until muscular exhaustion). Eye motility and eyelid drooping, and the velocity, gain and latency of visually guided horizontal saccades were also measured. Data were reported according to an "estimated treatment effect" which was generated by an ordinary least squares model using patients, treatment, period and pretreatment measurement as factors and

95% confidence intervals were reported. No significant effects of treatment were noted. Two participants experienced muscle cramps whilst being treated with creatine.

Kornblum et al (Kornblum 2005) studied 15 participants with CPEO or Kearns-Sayre syndrome (KSS) due to single deletions of mitochondrial DNA (mtDNA) in a double-blind, placebo-controlled cross-over study. Participants were treated with 150 mg/kg of creatine monohydrate or lactulose for six weeks. Assessments included phosphorus-31 magnetic resonance spectroscopy (³¹P-MRS: parameters included the phosphocreatine/adenosine triphosphate (PCr/ATP) ratio at rest and the time constant for oxidative PCr recovery following aerobic and ischaemic exercise), a modified Boston score of skeletal muscle function, maximum voluntary contraction tensiometric hand grip, and serum creatine kinase levels. The primary outcomes were analysed statistically using two-sided t-tests, with significance for P values less than 0.05. The secondary outcomes were not analysed statistically. There were no statistically significant differences between the creatine and lactulose treatments. No adverse effects were noted.

Given that these three trials used different doses of creatine, different treatment period, and participants with different genetic, biochemical, and clinical subtypes of mitochondrial disease, we did not attempt to calculate a summary effect for any of the outcomes.

Creatine, coenzyme Q10 and lipoic acid combination

Rodriguez et al (Rodriguez 2007) studied 16 participants with different mitochondrial disorders, including three with CPEO and one with KSS due to a single mtDNA deletion, three with MELAS due to m.3271T>C, two with LHON due to m.3460G>A, one with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), three with mitochondrial disorders due to rare point mutations (m.9053T>C, m.4452T>C and m.9035T>C), and three with a biochemically defined mitochondrial disorder. The 16 participants enrolled in a randomised, double-blind, placebo-controlled cross-over study receiving the active cocktail or placebo for two months, with a five-week washout period in between the treatment arms. The active cocktail comprised: 3 g creatine monohydrate with 2 g of dextrose, 300 mg alpha-lipoic acid, and 120 mg coenzyme Q10. Participants were evaluated after a four hour fast before and after each intervention at the same time of day. Clinical assessments included: handgrip, ankle dorsiflexion (at 90°) and knee extension of the right limbs using a custom-made force transducer. The best measurement from three 5 s trials was recorded. Additional measures included forced vital capacity and forced expiratory volume, free fat mass, percentage body fat and total body water. Plasma lactate, urinary 8-isoprostanes and 8-hydroxy-2-deoxyguanosine were also measured. Statistical analysis included two- or three-way repeated measures analysis of variance, with Tukey's post hoc test for significant values. P values of less than 0.05 were considered significant. One-tailed P values were used for antioxidant levels although two-tailed values for all others. Across the whole study group, the treatment statistically significantly lowered plasma lactate (one-tailed $P < 0.05$, mean + SD shown in graphical form) and urinary 8-isoprostanes, and there was evidence of attenuated the decline in peak angle dorsiflexion strength. There was evidence of higher free-fat mass with the treatment in participants with the MELAS phenotype ($P < 0.05$, mean + SD shown in graphical form). All other outcomes demonstrated non-significant differences.

Dichloroacetate

De Stefano et al (DeStefano 1995) studied 11 participants with mitochondrial disease, including four with myopathy, one with chronic CPEO and myopathy, two with KSS, two with Leigh syndrome, one with mitochondrial MELAS, and one with the mitochondrial DNA depletion syndrome. The study was a double-blind, placebo-controlled cross-over trial using 25 mg/kg twice daily dichloroacetate (DCA) or placebo for one week, followed by a three month washout period before the second period. Assessments were performed prior to each treatment period and on termination of the treatment, and included: a complete neurological examination, isometric force generation on dynamometry in proximal muscles (deltoid and iliopsoas), gait performance evaluation, resting venous blood lactate, alanine and pyruvate; incremental exercise in four participants with measurements of venous blood lactate, alanine and pyruvate; ³¹P-MRS of muscle and proton MRS (¹H-MRS) of the brain. Statistical analysis of participants was done using aggregate scores of all participants while on placebo compared with DCA. Two-tailed P values of less than 0.05 were considered statistically significant. For the MRS component of the study, the above statistical analysis was performed, as well as comparison with normal controls using one-tailed t-test. Variance of the results was reported as standard deviation. DCA produced statistically significant decreases in blood lactate, pyruvate and alanine at rest and after exercise ($P < 0.05$, values for each individual shown graphically), and statistically significant improvements on brain MRS were also noted in seven participants, including a statistically significant reduction of the brain lactate/creatine ratio (42%, $P < 0.05$, relative values shown graphically, no SD given), a statistically significant increase in brain choline/creatine ratio (18%, $P < 0.01$), and statistically significant increase in the acetylaspartate/creatine ratio (8%, $P < 0.05$) (for all of the statistics relating to MRS, only relative values were given, represented graphically, and SD was not provided). In two participants similar results were seen in a different volume of interest including the basal ganglia. Muscle MRS and self assessed clinical disability were unchanged. No adverse effects were reported.

Vissing et al (Vissing 2001) studied eight adults with various molecularly proven mitochondrial myopathies, having exercise intolerance. This was a randomised, double-blind, placebo-controlled cross-over study of DCA. Treatment was for either 15 days of DCA at 25 mg/kg twice daily or placebo, with a six-week washout period before entering the opposite arm of the study. Outcome measures included oxygen consumption (VO₂), workload and blood pressure during cycle ergometry, with measurements of venous lactate and pyruvate. ³¹P-MRS of forearm muscles before and after forearm exercise was measured. All participants filled a 20-item questionnaire commenting on activity levels and symptoms. Outcome measurements were performed before and at the end of each treatment phase. The participants' results at the end of each treatment period were compared in aggregate. P-values of less than 0.05 using a two-tailed t-test was considered to be statistically significant. One participant withdrew before data were collected because of sedation as a side-effect of DCA. Three other participants also experienced sedation on DCA but completed the study. Results demonstrated evidence of normalisation of the resting and exercise lactate and pyruvate levels. However, there was no difference in any of the other outcomes on cycle ergometry, ³¹P-MRS, or the questionnaire.

Duncan et al (Duncan 2004) published a randomised, placebo-controlled, double-blind cross-over study of DCA versus placebo in nine children and adults with varied respiratory chain disorders. Treatment with DCA (25 mg/kg) or placebo was for three months, with two-week washout in between. Measurements included physiological values and blood lactate at maximal and submaximal effort during treadmill exercise testing. Statistical analysis included analysis of variance for each of the variables, with two-sided tests at an alpha of 0.05. Mean blood lactate during submaximal exercise was statistically significantly lower during DCA therapy (1.71 (SD +/- 1.37) versus 2.39 (SD +/- 1.32)), although a variety of other measurements (VO₂ max, work, lactate, heart rate and blood pressure) were unchanged.

Kaufmann et al (Kaufmann 2006) reported a double-blind, randomised, placebo-controlled, three-year cross-over trial using 25 mg/kg/day of DCA for 12 months in 30 participants harbouring the m.3243A>G mtDNA mutation. Primary outcome measures included a purpose-designed integrated clinical assessment score (GATE, or Global Assessment of Treatment Efficacy, which was based on a health-related inventory, neurological and psychological evaluation, and activities of daily living). Additional endpoints included lactate measurements in venous blood and CSF, measured by ¹H-MRS. Nerve conduction tests were used to monitor safety. For the primary outcome, the Fisher exact test was used to determine whether significant differences existed in the aggregate GATE scores for participants while on DCA versus placebo therapy. Analysis of the secondary outcomes was performed using type 3 analysis of variance. The DCA was withdrawn from all 15 of the group receiving DCA in the first 24 month study period, compared to 4 of 15 participants on placebo. The trial was discontinued due to peripheral nerve toxicity. No significant differences were noted for the GATE score, or any of the secondary outcome measures.

Stacpoole et al (Stacpoole 2006) carried out a randomised, double-blind, controlled trial on 43 children with congenital lactic acidosis. The study group largely comprised children with mitochondrial respiratory chain disease (25 had one or more defects of the respiratory chain and 7 had a mutation of mtDNA), but also included 11 children with pyruvate dehydrogenase deficiency. Following six months' preconditioning on placebo, the children were randomised to receive 12.5 mg/kg of DCA or placebo every 12 hours for six months. The primary outcome measures were: a purpose designed integrated clinical assessment score (GATE, which was based on a health-related inventory, neurological and psychological evaluation, and activities of daily living); a measurement of linear growth; fasting blood lactate, and lactate after a carbohydrate meal; the frequency of severe or recurrent illnesses or hospital admissions; and safety tests of liver and peripheral nerve function. For the primary outcome, a generalised odds ratio (with 95% CI) was calculated for the effect of DCA on the GATE score. The secondary outcomes were analysed using two-sided t-tests, with P values less than 0.05 considered as statistically significant. There was evidence that treatment attenuated the rise in blood lactate following a carbohydrate meal, but had no effect on the other primary outcome measures. There were no significant side-effects, and specifically no objective evidence of peripheral nerve dysfunction as a consequence of the treatment.

Dimethylglycine

Based on anecdotal reports of an improvement in patients with congenital lactic acidosis, Liet et al (Liet 2003) studied five children with Saguenay-Lac-Saint-Jean cytochrome c oxidase (SLSJ-COX) deficiency in a randomised, double-blind study comparing dimethylglycine (DMG) to placebo. Children weighing < 33 kg were given 50 mg/kg/day in three divided doses, and those weighing > 33 kg were given 5 g per day in three doses over three days. The washout period was at least two weeks. Four measurements of VO₂ were performed using indirect calorimetry before and after treatment, and blood lactate, pyruvate, bicarbonate and pH. Dietary caloric intake was calculated for three days prior to each measurement. The primary outcome of change in VO₂ after placebo or DMG was analysed statistically using the Wilcoxon signed rank test for related samples for each participant. P values of less than 0.05 were considered to be statistically significant (two-tailed). The mean VO₂ was lower after administration of both DMG and placebo, but neither value reached statistical significance. There was no detectable effect on blood lactate, pyruvate, bicarbonate or pH. No significant side-effects were noted.

Whey-based cysteine supplement

Mancuso et al (Mancuso 2010) studied the effect of a whey-based cysteine supplement in 13 PEO patients in a randomised, double-blind, placebo-controlled cross-over study. Participants received 10 g/day of the supplement or placebo for 30 days, with no washout period. Measurements included markers of free radical reducing capacity (advanced oxidation protein products (AOPP); ferric reducing antioxidant power (FRAP); glutathione (GSH) level). Serum lactate was measured at various time points during cycle ergometry. Quality of life was measured using the Short Form 36 Health Survey (SF-36) questionnaire. Muscle power was assessed using the UK Medical Research Council (MRC) scale in various muscle groups. The baseline data were analysed using unpaired two-tailed t-tests, and Pearson correlation tests (for oxidative markers to the clinical measurements). Changes after therapy or placebo were analysed with paired t-tests. P values of less than 0.05 were considered significant. Results demonstrated that AOPP, FRAP and GSH were statistically significantly increased in the treatment period. Lactate, quality of life, and muscle power were unchanged.

DISCUSSION

Included studies

Assessing the efficacy of treatment for mitochondrial disorders is difficult for a number of reasons. First, the complex and variable phenotypes make it difficult to compare two or more individuals. Second, many mitochondrial disorders affect multiple organ systems which are difficult to compare (for example, it is difficult to compare an improvement in diabetic control with a reduction in seizure frequency). Thirdly, there is a lack of natural history data on individuals with mitochondrial disease, and related to this, many mitochondrial disorders involve infrequent paroxysmal events (such as stroke-like episodes, encephalopathy or seizures), making short studies unhelpful. These difficulties explain why we were only able to find 12 studies fulfilling our entry criteria, and most of these focussed on peripheral neuromuscular features, which are easier to assess.

The 12 studies assessed the effect of oral agents: coenzyme Q10, creatine monohydrate; a combination of coenzyme Q10 with creatine and lipoic acid; dichloroacetate (DCA); dimethylglycine (DMG); and whey-based cysteine supplement. There was objective evidence of locomotor functional improvement with creatine, but there were conflicting data. Creatine statistically significantly improved handgrip strength and nonischaemic isometric dorsiflexion torque (NIDFT) but did not improve muscle strength in two other studies. Paradoxically, the trials showing no effect used higher doses of the oral agent, ruling out inadequate dosage as an explanation for the lack of response. Although differences in study design may explain the discrepancies, it is intriguing, that the two longer trials showed no effect, possibly indicating that if there is a treatment response to creatine, it is not sustained. Although secondary measures were shown to statistically significantly improve with DCA in three studies in children (DeStefano 1995; Duncan 2004; Stacpoole 2006) and one short-term trial in adults (Vissing 2001), this was not associated with any improvement in physical function. The longer-term study carried out in adults used the same dose, but had to be terminated prematurely due to unacceptable side-effects without any evidence of clinical benefit (Kaufmann 2006). There was no evidence of a positive clinical response to DMG (Liet 2003) or whey-based cysteine supplement (Mancuso 2010).

It is important to mention some of the methodological similarities and differences between the studies. Of the 12 included studies, all but one (Stacpoole 2006) were cross-over studies, enabling each participant to act as his/her own control. In most of the studies, this was appropriate because the participants had a stable and chronic clinical course. However, this may not be the case for mitochondrial diseases with a fluctuating clinical course, such as Leigh syndrome, and patients with other fluctuating encephalopathies. All of the cross-over studies except one (Mancuso 2010) included a washout period, which is an essential component of a cross-over study design. The results of the statistical analyses were appropriately reported in each study. The variance of recorded measurements was reported as standard deviation in eight of the studies, standard error in two studies, and 95% CI in two studies. However, in order to maximise the power of a cross-over study, the usual approach involves a comparison of the difference between pre- and post-treatment measurements for each participant receiving either the active drug or placebo. This minimises the effect of inter-individual variability which is a major concern for small studies of a heterogeneous disorder such as mitochondrial disease. In simple terms, the analysis uses each participant as his/her own control. Studies which used statistical methods that would compare within-subject treatment differences used appropriate statistical methodology for the study design, and this included four studies using analysis of variance or (in the case of one study) the Wilcoxon signed-rank test. One study used analysis of variance for the secondary outcomes but did not include this for the primary outcome. Five studies used statistical methodology that did not include within-subject differences, potentially limiting the power of the studies to detect a treatment effect. One conclusion of this review is, therefore, to recommend an analysis of within-subject treatment effect in all future treatment studies. Another comment is that where statistically significant differences exist between placebo and treatment for a cross-over study, ideally the treatment difference with its 95% CI should be reported. This treatment difference was not reported in the studies which demonstrated statistically significant differences for any of their endpoints, and

we suggest that future studies include this statistic. Finally, the small number of participants per study may also have made the detection of treatment effect difficult, although the fact that all 12 studies did not detect a difference suggests that if any treatment effect exists, it is likely too small to be of any clinical significance.

With regard to the trial endpoints, numerous measures were employed in most trials, usually a combination of biochemical, physiologic, imaging, and questionnaire data. In most cases, the endpoints chosen were not directly clinically relevant, and the inclusion of so many endpoints increases the chances of a significant result arising due to chance. Ideally, further studies should focus on a small number of endpoints which are likely to reflect actual clinical benefit. In these regards, the GATE score (an aggregate measurement of neurological/psychological exam results, with questionnaire data on health and function), as described in the trials by Stacpoole (Stacpoole 2006) and Kaufmann et al (Kaufmann 2006), is one means of attempting to provide a clinically meaningful measurement of improvement.

Adverse events were considered for all of the above studies. With the exception of peripheral neuropathy in one of the DCA trials (Kaufmann 2006), there were no significant side-effects in the other trials. However the full evaluation of adverse reactions was difficult to assess because of the small number of participants per study, heterogeneous study populations, and lack of comparison of within-subject differences.

Excluded studies

Upon reassessment of the studies included in the previous version of this review, it was decided that two studies should be excluded. Both are negative studies of coenzyme Q10 in mitochondrial myopathy. One study (Muller 1990) found no clinical benefit of nine months of coenzyme Q10 versus placebo in a non-randomised, double-blind, cross-over design. Full assessment of this study is not possible because it exists only in abstract format. Data were not reported, except to state that there was no benefit from coenzyme Q10 therapy. There is a high risk of bias in this study because of the non-randomised design, and possibility of selective outcome reporting given that no data were reported. The other study of coenzyme Q10 (Chen 1997) was a non-randomised, double-blind, placebo-controlled cross-over study. Participants either had one month of placebo followed by three months of coenzyme Q10, or three months of coenzyme Q10 followed by a one-month washout and one month of placebo. Outcome assessments (subjective fatiguability in activities of daily living score, global muscle strength based on MRC scale, bedside endurance tests, exercise lactate test, serum Q10 level) occurred at monthly intervals. Results of the study reported that global MRC scale was significantly improved after three months coenzyme Q10, although the standard deviation (SD) was not reported for this outcome. The other outcomes were nonsignificant. This study has a high risk of bias because it was nonrandomised, and the design (in which participants starting with coenzyme Q10 spend more time in the study than participants starting on placebo) could have allowed the blinded assessors to determine whether they were in the placebo or study group based upon their time in the study. Furthermore, there is the possibility of selective outcome reporting because results for the coenzyme Q10 group were only reported at the end of three months, although data measurements occurred monthly.

On a practical level, the high risk of bias in these studies would presumably have altered the outcome in favour of treatment, and despite this both studies were negative. Several small case series have evaluated the effect of coenzyme Q10 in non-controlled or non-blinded formats (Ogasahara 1986; Ihara 1989; Bendahan 1992; Gold 1996; Papadimitriou 1996; Abe 1999) with results suggesting a possible beneficial effect of treatment. Recently a trial studying coenzyme Q10 with creatine and lipoic acid (Rodriguez 2007), which is summarized above, was positive for some surrogate endpoints although it is unclear if these are clinically relevant. Treatment with high-dose coenzyme Q10 (Glover 2010) was also not demonstrated to have any clinical effect in a RCT.

The literature contains hundreds of case studies describing benefits and harmful effects of a wide range of different therapies in the treatment of mitochondrial disease (examples are summarised in Table 2). There have also been a number of open studies showing improvement with pharmacological and non-pharmacological treatments, including a recent study of L-arginine for the acute and long-term treatment of stroke-like episodes in patients with mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) (Koga 2005). Given the inherent bias in studies of this type, we have deliberately not used these reports when reaching a view about treatment. These interventions should be studied rigorously in RCTs, particularly to evaluate the longer term effects.

In recent years there has been growing interest in the potential benefits of exercise for mitochondrial myopathy. A number of open-labelled studies have reported evidence of improved exercise tolerance and well-being following aerobic exercise training (Taivassalo 1998; Taivassalo 2006; Jeppesen 2006), and resistance training is also being explored as a potential means of correcting the underlying biochemical defect in muscle (Murphy 2008). However, only one RCT has been carried out to date (Cejudo 2005). Although this study had a positive outcome, it was not included in this review because of the high risk of bias in an unblinded study, where both participant and physician have a vested interest in showing a positive treatment effect. Whilst we recognise the difficulty of designing an exercise trial that is double blind, blinding is of particular importance for this intervention because the measured outcomes are known to depend on the effort of the study participant, and the approach taken by the investigator making the measurement.

Future directions

Over the last five years a number of multicentre research collaborations have been forged throughout Europe and North America (United Mitochondrial Disease Foundation: www.umdf.org), and clinical rating scales have been produced through an EU consortium (EUMITOCOMBAT www.eumitocombat.org/ and MITOCIRCLE <http://mitocircle.unimaas.nl/>). These developments have enabled a number of multicentre trials on large cohorts of phenotypically similar patients. Several trials are currently ongoing. Finally, the pharmaceutical industry has become interested in mitochondrial disorders in recent years, opening up the opportunity for commercially sponsored trials. These developments provide hope for the immediate future.

AUTHORS' CONCLUSIONS

Implications for practice

There have been very few RCTs for the treatment of mitochondrial disease. We conclude that there is currently no clear evidence supporting the use of any of these agents in mitochondrial disorders. Dichloracetate should not be used in adults because of the high incidence of potentially irreversible side-effects.

Implications for research

Further research is needed to establish the role of a wide range of therapeutic approaches in the treatment of mitochondrial disorders. Future studies should concentrate on designs featuring homogeneous study populations and clinically relevant outcomes. Trials should designate a much more limited number of primary

and secondary outcomes to study, and focus strictly on those which are clinically relevant.

ACKNOWLEDGEMENTS

With thanks to the staff of University of British Columbia libraries. PFC is a Wellcome Trust Senior Fellow in Clinical Science and a UK NIHR Senior Investigator who also receives funding from the Medical Research Council (UK), the Association Française contre les Myopathies, and the UK NIHR Biomedical Research Centre for Ageing and Age-related disease award to the Newcastle upon Tyne Foundation Hospitals NHS Trust.

The editorial base of the Cochrane Neuromuscular Disease Group is supported by the MRC Centre for Neuromuscular Diseases and the Muscular Dystrophy Campaign.

REFERENCES

References to studies included in this review

DeStefano 1995 {published data only}

DeStefano N, Matthews PM, Ford B, Genge A, Karpati G, Arnold DL. Short-term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders. *Neurology* 1995;**45**(6):1193-8. [PUBMED: 7783888]

Duncan 2004 {published data only}

Duncan GE, Perkins LA, Theriaque DW, Neiberger RE, Stacpoole PW. Dichloroacetate therapy attenuates the blood lactate response to submaximal exercise in patients with defects in mitochondrial energy metabolism. *Journal of Clinical Endocrinology and Metabolism* 2004;**89**(4):1733-8. [PUBMED: 15070938]

Glover 2010 {published data only}

Glover EI, Martin J, Maher A, Thornhill RE, Moran GR, Tarnopolsky MA. A randomized trial of coenzyme Q10 in mitochondrial disorders. *Muscle & Nerve* 2010;**42**(5):739-48. [PUBMED: 20886510]

Kaufmann 2006 {published data only}

Kaufmann P, Engelstad K, Wei Y, Jhung S, Sano MC, Shungu DC, et al. Dichloroacetate causes toxic neuropathy in MELAS. *Neurology* 2006;**66**(3):324-30. [PUBMED: 16476929]

Klopstock 2000 {published data only}

Klopstock T, Querner V, Schmidt F, Gekeler F, Walter M, Hartard M, et al. A placebo-controlled crossover trial of creatine in mitochondrial diseases. *Neurology* 2000;**55**(11):1748-51. [PUBMED: 11113239]

Kornblum 2005 {published data only}

Kornblum C, Schröder R, Müller K, Vorgerd M, Eggers J, Bogdanow M, et al. Creatine has no beneficial effect on skeletal muscle energy metabolism in patients with single mitochondrial deletions: a placebo-controlled, double-blind 31P-MRS crossover study. *European Journal of Neurology* 2005;**12**(4):300-9. [PUBMED: 15804248]

Liet 2003 {published data only}

Liet JM, Pelletier V, Robinson BH, Laryea MD, Wendel U, Morneau S, et al. The effect of short-term dimethylglycine treatment on oxygen consumption in cytochrome oxidase deficiency: a double-blind randomized crossover clinical trial. *Journal of Pediatrics* 2003;**142**(1):62-6. [PUBMED: 12520257]

Mancuso 2010 {published data only}

Mancuso M, Orsucci D, LoGerfo A, Rocchi A, Petrozzi L, Nesti C, et al. Oxidative stress biomarkers in mitochondrial myopathies, basally and after cysteine donor supplementation. *Journal of Neurology* 2010;**257**(5):774-781.

Rodriguez 2007 {published data only}

Rodriguez MC, MacDonald JR, Mahoney DJ, Parise G, Beal MF, Tarnopolsky MA. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. *Muscle & Nerve* 2007;**35**(2):235-42. [PUBMED: 17080429]

Stacpoole 2006 {published data only}

Stacpoole PW, Kerr DS, Barnes C, Bunch ST, Carney PR, Fennell EM, et al. Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. *Pediatrics* 2006;**117**(5):1519-31. [PUBMED: 16651305]

Tarnopolsky 1997 {published data only}

Tarnopolsky MA, Roy BD, MacDonald JR. A randomized controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. *Muscle & Nerve* 1997;**20**(12):1502-9. [PUBMED: 9390662]

Vissing 2001 {published data only}

Vissing J, Gansted U, Quistorff B. Exercise intolerance in mitochondrial myopathy is not related to lactic acidosis. *Annals of Neurology* 2001;**49**(5):672-6. [PUBMED: 11357960]

References to studies excluded from this review

Bresolin 1990 {published data only}

Bresolin N, Doriguzzi C, Ponzetto C, Angelini C, Moroni I, Castelli E, et al. Ubidecarenone in the treatment of mitochondrial myopathies: a multi-center double-blind trial. *Journal of the Neurological Sciences* 1990;**100**(1-2):70-8. [PUBMED: 2089142]

Cejudo 2005 {published data only}

Cejudo P, Bautista J, Montemayor T, Villagómez R, Jiménez L, Ortega F, et al. Exercise training in mitochondrial myopathy: a randomized controlled trial. *Muscle & Nerve* 2005;**32**(3):342-50. [PUBMED: 15962332]

Chen 1997 {published data only}

Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. *European Neurology* 1997;**37**(4):212-8. [PUBMED: 9208260]

Gimenes 2007 {published data only}

AC Gimenes, LM Nápolis, NL Silva, GO Siqueira, CR Nogueira, AS Bulle, et al. The effects of L-carnitine supplementation on respiratory muscle strength and exercise tolerance in patients with mitochondrial myopathies [Abstract]. *European Respiratory Journal* 2007;**Suppl 51**:21S[E297].

Koga 2005 {published data only}

Koga Y, Akita Y, Nishioka J, Yatsuga S, Povalko N, Tanabe Y, et al. L-arginine improves the symptoms of strokelike episodes in MELAS. *Neurology* 2005;**64**(4):710-2. [PUBMED: 15728297]

Muller 1990 {published data only}

Muller W, Reimers CD, Berninger T, Boergen K-P, Frey A, Zrenner E, et al. Coenzyme Q10 in ophthalmoplegia plus - a double blind, cross over therapeutic trial. *Journal of the Neurological Sciences* 1990;**98 Supplement**:442.

Stacpoole 2008 {published data only}

Stacpoole PW, Gilbert LR, Neiberger RE, Carney PR, Valenstein E, Theriaque DW, et al. Evaluation of long-term treatment of children with congenital lactic acidosis with dichloroacetate. *Pediatrics* 2008;**121**(5):e1223-8. [PUBMED: 18411236]

Suzuki 1998 {published data only}

Suzuki S, Hinokio Y, Ohtomo M, Hirai M, Hirai A, Chiba M, et al. The effects of coenzyme Q10 treatment on maternally inherited diabetes mellitus and deafness, and mitochondrial DNA 3243 (A to G) mutation. *Diabetologia* 1998;**41**(5):584-8. [PUBMED: 9628277]

Taivassalo 2006 {published data only}

Taivassalo T, Gardner JL, Taylor RW, Schaefer AM, Newman J, Barron MJ, et al. Endurance training and detraining in mitochondrial myopathies due to single large-scale mtDNA deletions. *Brain* 2006;**129**(Pt 12):3391-401. [PUBMED: 17085458]

Additional references
Abe 1991

Abe K, Fujimura H, Nishikawa Y, Yorifuji S, Mezaki T, Hirono N, et al. Marked reduction in CSF lactate and pyruvate levels after CoQ therapy in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). *Acta Neurologica Scandinavica* 1991;**83**(6):356-9.

Abe 1999

Abe K, Matsuo Y, Kadekawa J, Inoue S, Yanagihara T. Effect of coenzyme Q10 in patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): evaluation by noninvasive tissue oximetry. *Journal of the Neurological Sciences* 1999;**162**(1):65-8.

Anderson 1981

Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, et al. Sequence and organization of the human mitochondrial genome. *Nature* 1981;**290**(5806):457-65.

Barbiroli 1995

Barbiroli B, Montagna P, Cortelli P, Iotti S, Lodi R, Barboni P, et al. Lipoic (thioctic) acid increases brain energy availability and skeletal muscle performance as shown by in vivo ³¹P-MRS in a patient with mitochondrial cytopathy. *Journal of Neurology* 1995;**242**(7):472-7.

Barshop 2004

Barshop BA, Naviaux RK, McGowan KA, Levine F, Nyhan WL, Loupis-Geller A, et al. Chronic treatment of mitochondrial disease patients with dichloroacetate. *Molecular Genetics and Metabolism* 2004;**83**(1-2):138-49.

Bendahan 1992

Bendahan D, Desnuelle C, Vanuxem D, Confort-Gouny S, Figarella-Branger D, Pellissier JF, et al. ³¹P NMR spectroscopy and ergometer exercise test as evidence for muscle oxidative performance improvement with coenzyme Q in mitochondrial myopathies. *Neurology* 1992;**42**(6):1203-8.

Bernsen 1993

Bernsen PL, Gabreels FJ, Ruitenbeek W, Hamburger HL. Treatment of complex I deficiency with riboflavin. *Journal of the Neurological Sciences* 1993;**118**(2):181-7.

Chinnery 1997

Chinnery PF, Turnbull DM. Clinical features, investigation and management of patients with defects of mitochondrial DNA. *Journal of Neurology, Neurosurgery and Psychiatry* 1997;**63**(5):559-63.

Chinnery 1998

Chinnery PF, Howell N, Lightowers RN, Turnbull DM. Genetic counseling and prenatal diagnosis for mtDNA disease. *American Journal of Human Genetics* 1998;**63**(6):1908-11.

Chinnery 2001

Chinnery PF, Turnbull DM. Epidemiology and treatment of mitochondrial disease. *American Journal of Medical Genetics* 2001;**106**(1):94-101.

Cortelli 1997

Cortelli P, Montagna P, Pierangeli G, Lodi R, Barboni P, Liguori R, et al. Clinical and brain bioenergetics improvement with idebenone in a patient with Leber's hereditary optic neuropathy: a clinical and ³¹P-MRS study. *Journal of the Neurological Sciences* 1997;**148**(1):25-31.

Curless 1986

Curless RG, Flynn J, Bachynski B, Gregorios JB, Benke P, Cullen R. Fatal metabolic acidosis, hyperglycemia, and coma after steroid therapy for Kearns-Sayre syndrome. *Neurology* 1986;**36**(6):872-3.

DiMauro 1998

DiMauro S, Schon EA. Nuclear power and mitochondrial disease. *Nature Genetics* 1998;**19**(3):214-5.

DiMauro 2001

DiMauro S, Schon EA. Mitochondrial DNA mutations in human disease. *American Journal of Medical Genetics* 2001;**106**(1):18-26.

DiMauro 2003

DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. *New England Journal of Medicine* 2003;**348**(26):2656-68.

Eleff 1984

Eleff S, Kennaway NG, Buist NR, Darley-Usmar VM, Capaldi RA, Bank WJ, et al. ³¹P NMR study of improvement in oxidative phosphorylation by vitamins K3 and C in a patient with a defect in electron transport at complex III in skeletal muscle. *Proceedings of the National Academy of Sciences of the United States of America* 1984;**81**(11):3529-33.

Gold 1996

Gold R, Seibel P, Reinelt G, Schinder R, Landwehr P, Beck A, et al. Phosphorus magnetic resonance spectroscopy in the evaluation of mitochondrial myopathies: results of a 6-month therapy study with coenzyme Q. *European Neurology* 1996;**36**(4):191-6.

Gubbay 1989

Gubbay SS, Hankey GJ, Tan NT, Fry JM. Mitochondrial encephalomyopathy with corticosteroid dependence. *The Medical Journal of Australia* 1989;**151**(2):100-8, 10.

Hassani 2010

Hassani A, Horvath R, Chinnery PF. Mitochondrial myopathies: developments in treatment. *Current Opinion in Neurology* 2010;**23**(5):459-65.

Higgins 2011

Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

Holt 1988

Holt IJ, Harding AE, Morgan-Hughes JA. Deletion of muscle mitochondrial DNA in patients with mitochondrial myopathies. *Nature* 1988;**331**(6158):717-9.

Hsu 1995

Hsu CC, Chuang YH, Tsai JL, Jang HJ, Shen YY, Huang HL, et al. CPEO and carnitine deficiency overlapping in MELAS syndrome. *Acta Neurologica Scandinavica* 1995;**92**(3):252-5.

Ihara 1989

Ihara Y, Namba R, Kuroda S, Sato T, Shirabe T. Mitochondrial encephalomyopathy (MELAS): pathological study and successful therapy with coenzyme Q10 and idebenone. *Journal of the Neurological Sciences* 1989;**90**(3):263-71.

Jeppesen 2006

Jeppesen TD, Schwartz M, Olsen DB, Wibrand F, Krag T, Dunø M, et al. Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy. *Brain* 2006;**129**(Pt 12):3402-12.

Kaukonen 2000

Kaukonen J, Juselius JK, Tiranti V, Kyttala A, Zeviani M, Comi GP, et al. Role of adenine nucleotide translocator 1 in mtDNA maintenance. *Science* 2000;**289**(5480):782-5.

Kurlemann 1995

Kurlemann G, Paetzke I, Maler H, Masur H, Schuierer G, Weglage J, et al. Therapy of complex I deficiency: peripheral neuropathy during dichloroacetate therapy. *European Journal of Pediatrics* 1995;**154**(11):928-32.

Lamantea 2002

Lamantea E, Tiranti V, Bordoni A, Toscano A, Bono F, Servidei S, et al. Mutations of mitochondrial DNA polymerase gammaA are a frequent cause of autosomal dominant or recessive progressive external ophthalmoplegia. *Annals of Neurology* 2002;**52**(2):211-9.

Leonard 2000

Leonard JV, Schapira AVH. Mitochondrial respiratory chain disorders I: mitochondrial DNA defects. *Lancet* 2000;**355**(9200):299-304.

Lou 1981

Lou HC. Correction of increased plasma pyruvate and plasma lactate levels using large doses of thiamine in a patient with Kearns-Sayre syndrome. *Archives of Neurology* 1981;**38**(7):469.

Macmillan 1993

Macmillan C, Lach B, Shoubridge EA. Variable distribution of mutant mitochondrial DNAs (tRNA(Leu[3243])) in tissues of symptomatic relatives with MELAS: the role of mitotic segregation. *Neurology* 1993;**43**(8):1586-90.

Majamaa 1997

Majamaa K, Rusanen H, Remes A, Hassinen IE. Metabolic interventions against complex I deficiency in MELAS syndrome. *Molecular and Cellular Biochemistry* 1997;**174**(1-2):291-6.

Mandel 2001

Mandel H, Szargel R, Labay V, Elpeleg O, Saada A, Shalata A. The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA. *Nature Genetics* 2001;**29**(3):337-41.

Mashima 1992

Mashima Y, Hiida Y, Oguchi Y. Remission of Leber's hereditary optic neuropathy with idebenone [letter]. *Lancet* 1992;**340**(8815):368-9. [PUBMED: 1353825]

Mashima 2000

Mashima Y, Kigasawa K, Wakakura M, Oguchi Y. Do idebenone and vitamin therapy shorten the time to achieve visual recovery in Leber hereditary optic neuropathy?. *Journal of Neuro-Ophthalmology* 2000;**20**(3):166-70.

Mathews 1993

Mathews PM, Andermann F, Silver K, Karpati G, Arnold DL. Proton MR spectroscopic characterization of differences in regional brain metabolic abnormalities in mitochondrial encephalomyopathies. *Neurology* 1993;**43**(12):2484-90.

Mitsui 2002

Mitsui T, Umaki Y, Nagasawa M, Akaike M, Aki K, Azuma H, et al. Mitochondrial damage in patients with long-term corticosteroid therapy: development of oculoskeletal symptoms similar to mitochondrial disease. *Acta Neuropathologica* 2002;**104**(3):260-6.

Montini 2008

Montini G, Malaventura C, Salviati L. Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency. *New England Journal of Medicine* 2008;**358**(26):2849-50.

Mootha 2003

Mootha VK, Lepage P, Miller K, Bunkenborg J, Reich M, Hjerrild M, et al. Identification of a gene causing human cytochrome c oxidase deficiency by integrative genomics. *Proceedings of the National Academy of Sciences of the United States of America* 2003;**100**(2):605-10.

Moraes 1989

Moraes CT, DiMauro S, Zeviani M, Lombes A, Shanske S, Miranda AF, et al. Mitochondrial DNA deletions in progressive

external ophthalmoplegia and Kearns-Sayre syndrome. *New England Journal of Medicine* 1989;**320**(20):1293-9.

Mori 2004

Mori M, Yamagata T, Goto T, Saito S, Momoi MY. Dichloroacetate treatment for mitochondrial cytopathy: long-term effects in MELAS. *Brain & Development* 2004;**26**(7):453-8.

Mowat 1999

Mowat D, Kirby DM, Kamatu KR, Kan A, Thorburn DR, Christodoulou J. Respiratory chain complex III deficiency with pruritis: a novel vitamin responsive clinical feature. *Journal of Pediatrics* 1999;**134**(3):352-4.

Murphy 2008

Murphy JL, Blakely EL, Schaefer AM, He L, Wyrick P, Haller RG. Resistance training in patients with single, large-scale deletions of mitochondrial DNA. *Brain* 2008;**131**(Pt 11):2832-40.

Musumeci 2001

Musumeci O, Naini A, Slonim AE, Skavin N, Hadjigeorgiou GL, Krawiecki N, et al. Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. *Neurology* 2001;**56**(7):849-55.

Naviaux 2004

Naviaux RK, Nguyenk V. POLG mutations associated with Alpers' syndrome and mitochondrial DNA depletion. *Annals of Neurology* 2004;**55**(5):706-12.

Nishikawa 1989

Nishikawa K, Takahashi M, Yorifuji S, Nakamura Y, Veno S, Tarui S, et al. Long-term coenzyme Q10 therapy for a mitochondrial encephalomyopathy with cytochrome c oxidase deficiency: a 31P NMR study. *Neurology* 1989;**39**(3):399-403.

Nishino 1999

Nishino I, Spinazzola A, Hirano M. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. *Science* 1999;**283**(5402):689-92.

Ogasahara 1986

Ogasahara S, Nishikawa Y, Yorifuji S, Soga F, Nakamura Y, Takahashi M, et al. Treatment of Kearns-Sayre syndrome with coenzyme Q10. *Neurology* 1986;**36**(1):45-53.

Ogasahara 1989

Ogasahara S, Engel AG, Frens D, Mack D. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. *Proceedings of the National Academy of Sciences of the United States of America* 1989;**86**(7):2379-82.

Oguro 2004

Oguro H, Iijima K, Takahashi K, Nagai A, Bokwa H, Yamaguchi S, et al. Successful treatment with succinate in a patient with MELAS. *Internal Medicine* 2004;**43**(5):427-31.

Panetta 2004

Panetta J, Smith LJ, Boneh A. Effect of high-dose vitamins, coenzyme Q and high-fat diet in paediatric patients with mitochondrial diseases. *Journal of Inherited Metabolic Disease* 2004;**27**(4):487-98.

Papadimitriou 1996

Papadimitriou A, Hadjigeorgiou GM, Divavi R, Pagagalanis N, Comi G, Bresolin N. The influence of coenzyme Q10 on total serum calcium concentration in two patients with Kearns-Sayre syndrome and hypoparathyroidism. *Neuromuscular Disorders* 1996;**6**(1):49-53.

Penn 1992

Penn AM, Lee JW, Thuillier P, Wagner M, Machire KM, Menard MR, et al. MELAS syndrome with mitochondrial tRNA(Leu)(UUR) mutation: correlation of clinical state, nerve conduction, and muscle 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin. *Neurology* 1992;**42**(11):2147-52.

Remes 2002

Remes AM, Liimatta EV, Winqvist S, Tolonen U, Ranua JA, Reinikainen U, et al. Ubiquinone and nicotinamide treatment of patients with the 3243A-->G mtDNA mutation. *Neurology* 2002;**59**(8):1275-7.

Rotig 2000

Rotig A, Appelkvist EL, Geromel V, Chretien D, Kadahan N, Ederly P, et al. Quinone-responsive multiple respiratory chain deficiency due to widespread coenzyme Q10 deficiency. *Lancet* 2000;**356**(9227):391-5.

Saada 2001

Saada A, Shaag A, Mandel H, Nevo Y, Eriksson S, Elpeleg O. Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy. *Nature Genetics* 2001;**29**(3):342-4.

Schaefer 2008

Schaefer AM, McFarland R, Blakely EL, He L, Whittaker RG. Prevalence of mitochondrial DNA disease in adults. *Annals of Neurology* 2008;**63**(1):35-9.

Schapira 2006

Schapira AH. Mitochondrial disease. *Lancet* 2006;**368**(9529):70-82.

Schon 1997

Schon EA, Bonilla E, DiMauro S. Mitochondrial DNA mutations and pathogenesis. *Journal of Bioenergetics and Biomembranes* 1997;**29**(2):131-49.

Shoffner 1989

Shoffner JM, Lott MT, Voljavec AS, Soueidan SA, Costigan DA, Wallace DC. Spontaneous Kearns-Sayre/chronic external ophthalmoplegia plus syndromes associated with a mitochondrial DNA deletion: a slip-replication model and metabolic therapy. *Proceedings of the National Academy of Sciences of the United States of America* 1989;**86**(20):7952-6.

Sobreira 1997

Sobreira C, Hirano M, Shanske S, Keller RK, Haller RG, Davidson E, et al. Mitochondrial encephalomyopathy with coenzyme Q10 deficiency. *Neurology* 1997;**48**(5):1238-43.

Spelbrink 2001

Spelbrink JN, Li FY, Tiranti V, Nikali K, Yuan QP, Tariq M, et al. Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localised in mitochondria. *Nature Genetics* 2001;**28**(3):223-31.

Spinazzola 2009

Spinazzola A, Zeviani M. Mitochondrial diseases: a cross-talk between mitochondrial and nuclear genomes. *Advances in Experimental Medicine and Biology* 2009;**652**:69-84.

Taivassalo 1998

Taivassalo T, De Stefano N, Argov Z, Matthews PM, Chen J, Genge A, et al. Effects of aerobic training in patients with mitochondrial myopathies. *Neurology* 1998;**50**(4):1055-60.

Taivassalo 2001

Taivassalo T, Shoubridge EA, Chen J, Kennaway NG, Dimauro S, Arnold DL, et al. Aerobic conditioning in patients with mitochondrial myopathies: physiological, biochemical, and genetic effects. *Annals of Neurology* 2001;**50**(2):133-41.

Tarnopolsky 1999

Tarnopolsky M, Martin J. Creatine monohydrate increases strength in patients with neuromuscular disease. *Neurology* 1999;**52**(4):854-7.

Tucker 2010

Tucker EJ, Compton AG, Thorburn DR. Recent advances in the genetics of mitochondrial encephalomyopathies. *Current Neurology and Neuroscience Reports* 2010;**10**(4):277-85.

Van Goethem 2001

Van Goethem G, Dermaut B, Lofgren A, Martin JJ, Van Broeckhoven C. Mutation of POLG is associated with

progressive external ophthalmoplegia characterized by mtDNA deletions. *Nature Genetics* 2001;**28**(3):211-2.

Wallace 1994

Wallace DC. Mitochondrial DNA mutations in diseases of energy metabolism. *Journal of Bioenergetics & Biomembranes* 1994;**26**(3):241-50.

Wallace 1999

Wallace DC. Mitochondrial diseases in mouse and man. *Science* 1999;**283**(5407):1482-8.

Westermann 2010

Westermann B. Mitochondrial fusion and fission in cell life and death. *Nature Reviews Molecular Cell Biology* 2010;**11**(12):872-4.

Zeviani 1988

Zeviani M, Moraes CT, DiMauro S, Nakase H, Bonilla E, Schon EA, et al. Deletions of mitochondrial DNA in Kearns-Sayre syndrome. *Neurology* 1988;**38**(9):1339-46.

Zhu 2009

Zhu X, Peng X, Guan MX, Yan Q. Pathogenic mutations of nuclear genes associated with mitochondrial disorders. *Acta Biochimica et Biophysica Sinica* 2009;**41**(3):179-87.

References to other published versions of this review
Chinnery 2006

Chinnery P, Majamaa K, Turnbull D, Thorburn D. Treatment for mitochondrial disorders. *Cochrane Database of Systematic Reviews* 2006, Issue 1. [DOI: [10.1002/14651858.CD004426.pub2](https://doi.org/10.1002/14651858.CD004426.pub2)]

CHARACTERISTICS OF STUDIES
Characteristics of included studies [ordered by study ID]
DeStefano 1995

Methods	Randomised, placebo-controlled, double-blind cross-over
Participants	11 participants (4 myopathy, 1 CPEO, 2 KSS, 2 Leigh syndrome, one MELAS)
Interventions	Dichloroacetate 25 mg/kg twice daily or placebo for one week. 3 month washout
Outcomes	Neurological exam, dynamometry, gait evaluation, venous blood lactate, alanine and pyruvate at rest and on incremental exercise; ³¹ P-MRS of muscle and ¹ H-MRS of the brain
Notes	Statistically significantly decreased blood lactate, pyruvate and alanine at rest and after exercise (P < 0.05), and statistically significant improvements on brain MRS (brain lactate/creatine ratio fell by 42%, P < 0.05; brain choline/creatine ratio increased by 18%, P < 0.01; brain acetylaspartate/creatine ratio increased by 18%, P < 0.05) (SD not provided for these values)

Risk of bias

Bias	Authors' judgement	Support for judgement
------	--------------------	-----------------------

Treatment for mitochondrial disorders (Review)

DeStefano 1995 (Continued)

Random sequence generation (selection bias)	Unclear risk	Method of randomisation not specified
Allocation concealment (selection bias)	Unclear risk	Method of allocation not specified
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not all participants underwent all outcome assessments
Selective reporting (reporting bias)	Low risk	All outcome measures in methods section were reported in results section
Other bias	Low risk	None identified
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Groups were "randomized and unknown to the patient, physicians, or other evaluators."
Blinding of outcome assessment (detection bias) All outcomes	Low risk	"Each patient underwent two treatment courses, one with DCA and one with placebo. The order of these was randomized..."

Duncan 2004

Methods	Randomised, placebo-controlled, double-blind cross-over study
Participants	9 children and adults with various mitochondrial respiratory chain disorders
Interventions	Dichloroacetate (25 mg/kg daily) or placebo, 2 week washout
Outcomes	Physiologic exercise measurements (VO ₂ max, work output, lactate, heart rate, blood pressure), and rating of perceived exertion scale
Notes	Blood lactate during submaximal exercise statistically significantly lower in DCA group (1.71 (CI 0.81 to 2.61) versus 2.39 (CI 1.53 to 3.25)). All other outcomes not significant

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method of randomisation not specified
Allocation concealment (selection bias)	Unclear risk	Method of sequence allocation not specified
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants completed all outcome assessments
Selective reporting (reporting bias)	Low risk	All outcome measures in methods section were reported in results section

Treatment for mitochondrial disorders (Review)

Duncan 2004 (Continued)

Other bias	Low risk	None identified
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"subjects received either oral DCA or PL (25 mg/kg)..., administered randomly in a double-blind fashion"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	"subjects received either oral DCA or PL (25 mg/kg)..., administered randomly in a double-blind fashion"

Glover 2010

Methods	Randomised, double-blind, placebo-controlled cross-over study
Participants	30 adult participants with various mitochondrial disorders: 15 MELAS, 11 PEO, 1 complex I deficiency, 1 NARP, 1 ataxia-neuropathy, 1 LHON
Interventions	Coenzyme Q10 600 mg orally twice daily for 60 days and placebo for 60 days. Washout period of 67 +/- 8.3 days
Outcomes	Outcome assessment at end of each trial period. Urine analysis of 8-isoprostane and 8-hydroxy-2-deoxyguanosine. Blood analysis of lactate, glucose, PCO ₂ , CoQ10, bilirubin, creatine kinase and gamma-glutamyltransferase. Questionnaires for quality of life and ADL. Maximal isometric force and near-infrared spectroscopy on 90 s forearm ischaemic exercise test, with venous lactate, PCO ₂ , PO ₂ at 1 min and 3 min post-test. Dual-energy X-ray absorptometry for body composition. 15 min cycle ergometry with monitoring heart rate, inspired O ₂ , expired CO ₂ . VO ₂ and VCO ₂ measured at several time points. Venous lactate measured prior, and at various points during and after testing
Notes	MRS of CSF lactate, N-acetyl aspartate and choline. Serum CoQ10 was statistically significantly increased. Lactate was statistically significantly decreased at 1 min of cycle ergometry, but there was no difference at other time points. All other endpoints did not differ significantly

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method of randomisation not specified
Allocation concealment (selection bias)	Unclear risk	Method of allocation not specified
Incomplete outcome data (attrition bias) All outcomes	Low risk	Incomplete outcome data adequately addressed
Selective reporting (reporting bias)	Low risk	All outcome measures in methods section were reported in results section
Other bias	Unclear risk	The inclusion of participants with mitochondrial diseases that do not have myopathy may have biased the study against a treatment effect

Glover 2010 (Continued)

Blinding of participants and personnel (performance bias) All outcomes	Low risk	This was a double-blind trial using "identical-appearing placebo capsules"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Participants were randomly assigned to placebo or CoQ10 treatment

Kaufmann 2006

Methods	Randomised, placebo controlled cross-over study	
Participants	30 participants with m.3243A>G	
Interventions	25mg/kg/day of dichloracetate for 12 months	
Outcomes	GATE, lactate measurements in venous blood, CSF and measured by ¹ H-MRS. Nerve conduction tests were used to monitor safety	
Notes	No benefit The trial was discontinued due to peripheral nerve toxicity	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Based on a computer-generated randomization list"
Allocation concealment (selection bias)	Low risk	"the research pharmacy at the University of Florida mailed study medication for each participant to the clinical investigators"
Incomplete outcome data (attrition bias) All outcomes	Low risk	Incomplete outcome data for some participants, although this was due to withdrawal of participants due to side-effects in the DCA group, and early termination of the study
Selective reporting (reporting bias)	Low risk	All outcome measures were reported for all participants up to the termination of the trial
Other bias	Low risk	None identified
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"clinical researchers remained blinded to treatment assignment throughout the trial"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Participants were randomly assigned to start in either the DCA or placebo arm

Klopstock 2000

Methods	Randomised, placebo-controlled, double-blind cross-over
Participants	16 participants (13 CPEO, 3 myopathy)
Interventions	Creatine monohydrate 20 g /day or placebo for 4 weeks. Washout \geq 24 days in all participants
Outcomes	Visual analogue scales of subjective weakness and general activity, neuromuscular symptom score, function time test, function ranking test, ataxia score, muscle strength, motor ability score. Resting and post-exercise lactate, maximal voluntary muscle torque, aerobic exercise performance, eye motility and eyelid drooping
Notes	No effect

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method of randomisation not specified
Allocation concealment (selection bias)	Unclear risk	Method of allocation not specified
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants completed all outcome assessments
Selective reporting (reporting bias)	Low risk	All outcome measures in methods section were reported in results section
Other bias	Low risk	None identified
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"double-blind, placebo-controlled 2x2 crossover trial"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Participants were randomly assigned to start in either the creatine or placebo arm

Kornblum 2005

Methods	Randomised, placebo controlled cross-over study
Participants	15 participants with CPEO or KSS due to single deletions of mtDNA
Interventions	150 mg/kg of creatine monohydrate or placebo containing lactose for 6 weeks. 4-week washout
Outcomes	^{31}P -MRS (parameters included the PCr/ATP ratio at rest and the time constant for oxidative PCr)
Notes	No significant effect

Risk of bias
Treatment for mitochondrial disorders (Review)

Kornblum 2005 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Patients were individually randomized... using standard PC software."
Allocation concealment (selection bias)	Low risk	Allocation conducted by the central pharmacy
Incomplete outcome data (attrition bias) All outcomes	Low risk	Incomplete outcome data adequately addressed
Selective reporting (reporting bias)	Low risk	All outcome measures in methods section were reported in results section
Other bias	Low risk	None identified
Blinding of participants and personnel (performance bias) All outcomes	Low risk	In this double-blind trial, creatine and placebo provided in "identical-looking capsules."
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Participants were randomly assigned to start in either the creatine or placebo arm. "Evaluations and calculations on efficacy measures were performed blinded."

Liet 2003

Methods	Randomised, placebo-controlled cross-over study
Participants	5 children with SLSJ-COX deficiency
Interventions	Dimethylglycine or placebo (50 mg/kg/day if < 33 kg, 5 g/day if > 33 kg). 2-week washout
Outcomes	Oxygen consumption (VO ₂) by indirect calorimetry, venous lactate, pyruvate, bicarbonate and pH
Notes	No significant effect

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"The order of administration of placebo and DMG was randomized by using a one-block sequence generated from a random number table."
Allocation concealment (selection bias)	Unclear risk	Method of allocation not specified
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants completed all outcome assessments
Selective reporting (reporting bias)	Low risk	All outcome measures in methods section were reported in results section

Liet 2003 (Continued)

Other bias	Low risk	None identified
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"Capsules containing placebo or DMG were indistinguishable." This was a double-blind cross-over trial, involved dieticians were also blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Participants were randomly assigned to start in either the DMG or placebo arm.

Mancuso 2010

Methods	Randomised, double-blind, placebo-controlled cross-over study	
Participants	Thirteen participants with progressive external ophthalmoplegia	
Interventions	10 g/day of whey-based oral supplement or placebo for 30 days, then immediately proceed to next group	
Outcomes	Measurements of markers of free radical reducing capacity (advanced oxidation protein products (AOPP); ferric reducing antioxidant power (FRAP); glutathione (GSH) level). Serum lactate measured at various time points during cycle ergometry. Quality of life measured using SF-36 questionnaire. Muscle power measured with MRC scale in various muscle groups	
Notes	AOPP, FRAP and GSH were statistically significantly increased in the treatment period. Lactate, quality of life, and muscle power were unchanged	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method of randomisation not specified
Allocation concealment (selection bias)	Unclear risk	Method of allocation not specified
Incomplete outcome data (attrition bias) All outcomes	Low risk	Incomplete outcome data adequately addressed
Selective reporting (reporting bias)	Low risk	All outcome measures in methods section were reported in results section
Other bias	Unclear risk	There was no washout period between trials which could potentially decrease the treatment effect
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	It is not specified whether the placebo had identical characteristics (appearance/taste) to the treatment
Blinding of outcome assessment (detection bias)	Low risk	Participants were randomly assigned to placebo or CoQ10 treatment

Mancuso 2010 (Continued)

All outcomes

Rodriguez 2007

Methods	Randomised, double-blind, placebo-controlled cross-over study
Participants	16 participants with different mitochondrial disorders (3 CPEO, 1 KSS, 3 MELAS, 1 MNGIE, 3 with mitochondrial disorders due to rare point mutations (m.9053T>C, m.4452T>C and m.9035T>C))
Interventions	Combination of 3 g creatine monohydrate with 2 g of dextrose, 300 mg alpha-lipoic acid, and 120 mg coenzyme Q10
Outcomes	Handgrip, ankle dorsiflexion (at 90°) and knee extension, forced vital capacity and forced expiratory volume, free fat mass, percentage body fat and total body water, plasma lactate, urinary 8-isoprostanes and 8-hydroxy-2-deoxyguanosine
Notes	Across the whole study group, the treatment statistically significantly lowered plasma lactate and urinary 8-isoprostanes, and there was evidence it attenuated the decline in peak angle dorsiflexion strength

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method of randomisation not specified
Allocation concealment (selection bias)	Unclear risk	Method of allocation not specified
Incomplete outcome data (attrition bias) All outcomes	Low risk	Incomplete outcome data adequately addressed
Selective reporting (reporting bias)	Low risk	All outcome measures in methods section were reported in results section
Other bias	Low risk	None identified
Blinding of participants and personnel (performance bias) All outcomes	Low risk	In this double-blind study, placebo provided as "identical-appearing and tasting powder... and gel capsules."
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Participants were randomly assigned to start in either the treatment or placebo arm

Stacpoole 2006

Methods	Randomised, double-blind, placebo-controlled parallel-group study
---------	---

Stacpoole 2006 (Continued)

Participants	43 participants with congenital lactic acidosis, including 25 with one or more defects of the respiratory chain and 7 with a mutation of mtDNA
Interventions	12.5 mg/kg of dichloracetate every 12 hours for 6 months
Outcomes	GATE; linear growth; fasting blood lactate, and lactate after a carbohydrate meal; the frequency of severe or recurrent illnesses or hospital admissions; and safety tests of liver and peripheral nerve function
Notes	Statistically significant attenuation of the rise in blood lactate following a carbohydrate meal. No clinical benefit

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method of randomisation not specified
Allocation concealment (selection bias)	Unclear risk	Method of allocation not specified
Incomplete outcome data (attrition bias) All outcomes	Low risk	Incomplete outcome data adequately addressed
Selective reporting (reporting bias)	Low risk	All outcome measures in methods section were reported in results section
Other bias	Low risk	None identified
Blinding of participants and personnel (performance bias) All outcomes	Low risk	This was a double-blind trial. "[P]lacebo solution was formulated in an identical manner [to the DCA solution], except for the absence of DCA."
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Participants were randomly assigned to placebo or DCA treatment

Tarnopolsky 1997

Methods	Randomised, placebo-controlled, double-blind cross-over
Participants	7 participants (6 MELAS, 1 myopathy)
Interventions	Creatine monohydrate 5 g twice daily for two weeks followed by 2 g twice daily for 1 week
Outcomes	Visual analogues ADL scale, ischaemic isometric handgrip strength, evoked and voluntary muscle contraction strength, NIDFT, aerobic cycle ergometry with basal and post-ischaemic lactate measurements
Notes	Statistically significantly increased handgrip strength (19% increase in torque in N m, $P < 0.01$), NIDFT (11%, $P < 0.01$) and post-exercise lactate ($P < 0.05$)

Risk of bias
Treatment for mitochondrial disorders (Review)

Tarnopolsky 1997 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method of randomisation not specified
Allocation concealment (selection bias)	Unclear risk	Method of allocation not specified
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants completed all outcome assessment.
Selective reporting (reporting bias)	Low risk	All outcome measures in methods section were reported in results section
Other bias	Low risk	None identified
Blinding of participants and personnel (performance bias) All outcomes	Low risk	This was a double-blind study. Treatment and placebo provided as "identical and indistinguishable powders."
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Participants were randomly assigned to start in either the treatment or placebo arm

Vissing 2001

Methods	Randomised, placebo-controlled, double-blind cross-over	
Participants	8 participants (3 CPEO, 1 MERRF, 5 mitochondrial myopathy)	
Interventions	Dichloroacetate 25 mg/kg twice daily or placebo for 15 days. Washout of 6 weeks in all participants	
Outcomes	VO ₂ , workload and blood pressure during cycle ergometry, with measurements of venous lactate and pyruvate. ³¹ P-MRS of forearm muscles before and after forearm exercise was measured. All participants filled a 20-item questionnaire commenting on activity levels and symptoms. Outcome measurements were performed before and at the end of each treatment phase	
Notes	Normalisation of resting and exercise lactate and pyruvate levels. All other outcomes were non-significant or did not favour treatment. One participant withdrew due to sedation on treatment	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method of randomisation not specified
Allocation concealment (selection bias)	Unclear risk	Method of allocation not specified
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants completed all outcome assessments

Treatment for mitochondrial disorders (Review)

Vissing 2001 (Continued)

Selective reporting (reporting bias)	Low risk	All outcome measures in methods section were reported in results section
Other bias	Low risk	None identified
Blinding of participants and personnel (performance bias) All outcomes	Low risk	This was a double-blind study. Placebo was "the same volume, color and flavor as the DCA mixture."
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Participants were randomly assigned to start in either the treatment or placebo arm

ADL: activities of daily living

ATP: adenosine triphosphate

CPEO: chronic progressive external ophthalmoplegia

DCA: dichloroacetate

DMG: dimethylglycine

GATE: Global Assessment of Treatment Efficacy score, based on a health-related inventory, neurological and psychological evaluation, and activities of daily living

¹H-MRS: proton magnetic resonance spectroscopy

KSS: Kearns-Sayre syndrome

MELAS: mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes

MERRF: myoclonic epilepsy with ragged-red fibres

MRC: UK Medical Research Council

mtDNA: mitochondrial DNA

NIDFT: nonischaemic isometric dorsiflexion torque

³¹P-MRS: phosphorus magnetic resonance spectroscopy

PCr: phosphocreatine

SD: standard deviation

SF-36 Short Form 36 Health Survey

SLSJ-COX: Saguenay-Lac-Saint-Jean cytochrome c oxidase deficiency

VO₂: oxygen consumption

Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Bresolin 1990	High risk of bias because entry criterion for the double-blind portion of the study was decided retrospectively based upon the results of the open-label phase. Furthermore, the double-blind portion of the study was not randomised.
Cejudo 2005	High risk of bias due to lack of blinding.
Chen 1997	High risk of bias. Participants were not randomised. The study design (3 months of coenzyme Q10 or 1 month placebo, with one month washout if the participant started on coenzyme Q10) would allow a blinded assessor to know whether participant was on treatment or placebo depending on the duration of time in the study. There is a possibility of selective outcome reporting since participants were assessed monthly although results were only reported for end of three-month treatment period
Gimenes 2007	High risk of bias due to possibility of selective outcome reporting, and inability to fully assess risk of bias in other domains, since this publication consists of an abstract only, and the study has not been published in a peer-reviewed format

Study	Reason for exclusion
Koga 2005	High risk of bias due to the non-randomised, open-label design
Muller 1990	High risk of bias. Participants were not randomised. Data and statistical analysis were not reported. There is a possibility of selective outcome reporting given that study endpoints were not clearly stated, and only 7 participants were reported. This evidence is in abstract format and therefore it is not possible to fully assess the risk of bias
Stacpoole 2008	High risk of bias due to the non-randomised, open-label, non-controlled study design
Suzuki 1998	High risk of bias due to the non-randomised, open-label, non-placebo controlled study design
Taivassalo 2006	High risk of bias due to the non-randomised, non-controlled, non-blinded study design

ADDITIONAL TABLES

Table 1. Clinical syndromes associated with mitochondrial disease

Clinical syndrome	Primary features	Additional features
Chronic progressive external ophthalmoplegia (CPEO)	External ophthalmoplegia and bilateral ptosis	Mild proximal myopathy
Infantile myopathy and lactic acidosis (fatal and non-fatal forms)	Hypotonia in the first year of life. Feeding and respiratory difficulties	Fatal form may be associated with a cardiomyopathy and/or the Toni-Fanconi-Debre syndrome
Kearns-Sayre syndrome (KSS)	CPEO onset before age 20 with pigmentary retinopathy Plus one of the following: CSF protein greater than 1 g/l, cerebellar ataxia, heart block	Bilateral deafness Myopathy Dysphagia Diabetes mellitus and hypoparathyroidism Dementia
Leber hereditary optic neuropathy (LHON)	Subacute painless bilateral visual failure Males: females approx. 4:1 Median age of onset 24 years	Dystonia Cardiac pre-excitation syndromes
Leigh syndrome (LS)	Subacute relapsing encephalopathy with cerebellar and brain-stem signs presenting during infancy	Basal ganglia lucencies
Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS)	Stroke-like episodes before age 40 years Seizures and/or dementia Ragged-red fibres and/or lactic acidosis	Diabetes mellitus Cardiomyopathy (hypertrophic leading to dilated) Bilateral deafness Pigmentary retinopathy Cerebellar ataxia
Myoclonic epilepsy with ragged-red fibres (MERRF)	Myoclonus Seizures Cerebellar ataxia Myopathy	Dementia, optic atrophy Bilateral deafness Peripheral neuropathy Spasticity Multiple lipomata

Table 1. Clinical syndromes associated with mitochondrial disease (Continued)

Neurogenic weakness with ataxia and retinitis pigmentosa (NARP)	Late childhood or adult onset peripheral neuropathy with associated ataxia and pigmentary retinopathy	Basal ganglia lucencies Abnormal electroretinogram Sensorimotor neuropathy
Pearson Syndrome	Sideroblastic anaemia of childhood Pancytopenia Exocrine pancreatic failure	Renal tubular defects

Table 2. Oral agents used in single case studies and open trials

Class	Agent (route)	Indication	Proposed mechanism	Dose	Effects
Quinone derivatives	Ubiquinone (coenzyme Q10) (oral)	Isolated ubiquinone deficiency	Redox bypass corrects the deficiency	60 - 250 mg/day	Significant clinical improvement (Ogasahara 1989; Sobreira 1997; Rotig 2000; Montini 2008)
		All mitochondrial disorders	Redox bypass, free radical scavenger	30 - 260 mg/day	Subjective improvement, particularly reduced fatigue and reduced muscle cramps. Isolated reports of clinical and metabolic improvement (Ogasahara 1986; Ihara 1989; Nishikawa 1989; Abe 1991; Bendahan 1992; Gold 1996; Papadimitriou 1996)
	Idebenone (oral)	All mitochondrial disorders, especially LHON	Free radical scavenger, redox bypass of complex I	90 - 270 mg/day	Improved brain and skeletal muscle metabolism in isolated cases (Ihara 1989; Cortelli 1997). May enhance the rate and degree of visual recovery in LHON (Mashima 1992; Mashima 2000)
Vitamin supplements	Thiamine (B1)(oral)	KSS and other mitochondrial disorders	Coenzyme for pyruvate dehydrogenase complex (PDHC)	Up to 900 mg/day	Isolated reports of improvement (Lou 1981). No significant effect in a larger study (Mathews 1993)
	Riboflavin (B2)(oral)	Complex I and complex II deficiency	Acts as flavin precursor for complex I and II	100 mg/day	Clinical and biochemical improvements in small groups of patients (Penn 1992; Bernsen 1993). A larger study of 16 different patients failed to show a benefit (Mathews 1993)
	Ascorbate (C) and menadione (K3) (oral)	Complex III deficiency. Other mitochondrial disorders	Antioxidant Bypass of complex III (with vitamin C)	10 mg qds (four times daily)	Symptomatic and bioenergetic improvements in isolated cases (Eleff 1984; Mowat 1999)
	Nicotinamide (B3) (oral)	MELAS and complex I deficiency	Increase of NAD + NADH pool		Clinical and biochemical improvements in isolated cases treated with nicotinamide alone (Majamaa 1997) or in combination with

Table 2. Oral agents used in single case studies and open trials (Continued)

					ubiquinone (Remes 2002) or riboflavin (Penn 1992)
Metabolic supplements	Succinate (oral)	Complex I deficiency, KSS and MELAS	Donates electrons directly to complex II	6 g/day	Improvements reported in isolated cases (Shoffner 1989; Oguro 2004)
	Creatine	Mitochondrial myopathy	Enhances muscle phosphocreatine	Up to 10 g/day	Reduced fatigue and enhanced muscle strength and aerobic exercise capacity (Tarnopolsky 1999)
	Carnitine	Secondary carnitine deficiency	Replacement	Up to 3 g/day	Improvements in isolated cases (Hsu 1995)
	Lipoic acid (oral)	CPEO	Enhancing PDHC activity	600 mg/day	Clinical and biochemical improvement in an isolated case (Barbiroli 1995)
	High fat diet	Mitochondrial disorders, especially complex I deficiency	Increased proportion of electrons donated after (ie bypass) Complexes I and II	50 - 60% of caloric intake	Short-term clinical improvement in small series treated with high-fat diet plus ubiquinone and vitamins B1, B1 and C (Panetta 2004)
	Dimethylglycine	Congenital lactic acidosis	Minor contributor to respiratory chain and possible free radical scavenger.	Not specified	Unspecified improvement in unpublished observations (Liet 2003)
Dichloroacetate		Mitochondrial disorders especially with lactic acidosis	Reduces lactic acidosis by enhancing PDHC activity	25 mg/kg/day	Short-term improvements in muscle and brain oxidative metabolism (DeStefano 1995). Potential complications include a painful peripheral neuropathy (Kurlemann 1995). Temporary benefits noted in two recent open trials (Barshop 2004; Mori 2004)
Corticosteroids		No clear indication	Unclear, if any	Up to 100 mg/day Prednisone	Improvements have been reported in isolated cases (Gubbay 1989), but steroids may exacerbate the metabolic encephalopathy (Curless 1986) and have long-term consequences (Mitsui 2002)
Vasodilators	L-arginine	3243A>G MELAS stroke-like episodes	Endothelial relaxation through enhanced nitric oxide production	0.15 - 0.3 g/kg/d IV in the acute phase, oral between episodes	Improved stroke-like symptoms (Koga 2005)

CPEO: chronic progressive external ophthalmoplegia

IV: intravenous

KSS: Kearns-Sayre syndrome

LHON: Leber hereditary optic neuropathy

MELAS; mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes

Treatment for mitochondrial disorders (Review)

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

NAD: nicotinamide adenine dinucleotide
 PDHC: pyruvate dehydrogenase complex

APPENDICES

Appendix 1. OVID MEDLINE strategy

1 randomized controlled trial.pt.
 2 controlled clinical trial.pt.
 3 randomized.ab.
 4 placebo.ab.
 5 drug therapy.fs.
 6 randomly.ab.
 7 trial.ab.
 8 groups.ab.
 9 or/1-8
 10 animals not (animals and humans)).sh.
 11 9 not 10
 12 exp Mitochondrial Diseases/
 13 mitochondrial myopath\$.mp.
 14 (mitochondrial encephalomyopath\$ or mitochondrial encephalopath\$).mp.
 15 (mitochondrial disease\$ or mitochondrial disorder\$).mp.
 16 or/12-15
 17 ((CPEO or ophthalmoplegia) adj5 progressive).mp.
 18 cytochrome-c oxidase deficiency.mp. or Ubiquinol-Cytochrome-c reductase/df
 19 (Kearns adj3 syndrome\$).mp.
 20 KSS.mp.
 21 or/17-20
 22 ((leber adj5 neuropath\$) or (Pearson adj5 syndrome\$) or (pearson adj5 disease\$)).mp.
 23 optic nerve/ and (atrophy/ or optic atrophy/)
 24 LHON.mp.
 25 (MELAS adj6 syndrome\$).mp.
 26 lactic acidosis.mp. or Lactic Acidosis/
 27 (stroke adj episode\$).mp.
 28 26 and 27
 29 22 or 23 or 24 or 25 or 28
 30 ((MERFF adj5 syndrome\$) or MERFF).mp.
 31 MIDD.mp.
 32 (maternal\$ adj5 diabetes adj5 deafness).mp.
 33 or/30-32
 34 ((leigh adj5 syndrome\$) or (leigh adj5 disease\$)).mp.
 35 MNGIE.mp.
 36 (mitochondrial adj5 neurogastrointestinal adj5 encephalomyopath\$).mp.
 37 or/34-36
 38 retinitis pigmentosa.mp. or Retinitis Pigmentosa/
 39 ATAXIA/
 40 ataxia.mp.
 41 38 and (39 or 40)
 42 NARP.mp.
 43 (pyruvate adj5 carboxylase adj5 deficiency adj5 disease).mp.
 44 pyruvate dehydrogenase complex deficiency disease.mp.
 45 or/41-44
 46 16 or 21 or 29 or 33 or 37 or 45
 47 drug\$.mp. or Drug Therapy/
 48 treatment.mp. or Therapeutics/
 49 (coenzyme Q10 or co enzyme Q10 or carnitine\$ or creatine\$ or idebenone\$ or ubidecarenone\$ or vitamin C or vitamin E or menadione \$ or nicotinamide\$ or dichloracetate\$ or thiamine\$ or riboflavin\$ or succinate\$ or corticosteroid\$).mp.
 50 (growth adj5 hormone\$).mp.
 51 exercise.mp. or Exercise Therapy/
 52 diet\$.mp. or Diet Therapy/

53 or/47-52
 54 11 and 46 and 53

Appendix 2. EMBASE search strategy

1 crossover-procedure/
 2 double-blind procedure/
 3 randomized controlled trial/
 4 single-blind procedure/
 5 (random\$ or factorial\$ or crossover\$ or cross over\$ or cross-over\$ or placebo\$ or (doubl\$ adj blind\$) or (singl\$ adj blind\$) or assign\$ or allocat\$ or volunteer\$).tw.
 6 or/1-5
 7 human/
 8 6 and 7
 9 nonhuman/ or human/
 10 6 not 9
 11 8 or 10
 12 exp Disorders of Mitochondrial Functions/
 13 mitochondrial myopath\$.mp.
 14 12 or 13
 15 Encephalomyopathy/
 16 (mitochondrial encephalomyopath\$ or mitochondrial encephalopath\$).mp.
 17 15 or 16
 18 External Ophthalmoplegia/ or CPEO.mp.
 19 chronic progressive external ophthalmoplegia.mp.
 20 or/18-19
 21 (Kearns adj5 syndrome\$).mp.
 22 Kearns Sayre Syndrome/
 23 KSS.mp.
 24 or/21-23
 25 ((Pearson adj5 syndrome\$) or (pearson adj5 disease\$)).mp.
 26 ((Leber adj5 neuropath\$).mp. or optic nerve atrophy/) and leber.mp.
 27 LHON.mp.
 28 25 or 26 or 27
 29 (MELAS adj5 syndrome\$).mp. or Melas Syndrome/
 30 lactic acidosis.mp. or Lactic Acidosis/
 31 (stroke adj episode\$).mp.
 32 30 and 31
 33 29 or 32
 34 ((Merff adj5 syndrome\$) or MERFF).mp.
 35 Merrf Syndrome/
 36 34 or 35
 37 MIDD.mp.
 38 (maternal\$ adj5 diabetes adj5 deafness).mp.
 39 37 or 38
 40 ((leigh adj5 syndrome\$) or (leigh adj5 disease)).mp. or Leigh Disease/
 41 NARP.mp. or narp syndrome/
 42 ataxia.mp.
 43 (retinitis adj3 pigmentosa).mp. or retinitis pigmentosa/
 44 42 and 43
 45 41 or 44
 46 MNGIE.mp.
 47 mitochondrial neurogastrointestinal encephalomyopathy/ or (mitochondrial adj5 neurogastrointestinal adj5 encephalomyopath\$).mp.
 48 ubiquinol-cytochrome-c reductase.mp. or Ubiquinol Cytochrome C Reductase/
 49 enzyme deficiency.mp. or Enzyme Deficiency/
 50 48 and 49
 51 46 or 47
 52 12 or 14 or 17 or 20 or 24 or 28 or 33 or 36 or 39 or 40 or 45 or 50 or 51
 53 diet.mp. or exp Diet Therapy/
 54 drug.mp. or Drug Therapy/

55 (coenzyme Q10 or co enzyme Q10 or carnitine\$ or creatine\$ or idebenone\$ or ubidecarenone\$ or vitamin C or vitamin E or menadione \$ or nicotinamide\$ or thiamine\$ or riboflavin\$ or succinate\$ or corticosteroid\$ or dichloracetate\$).mp.
 56 (growth adj5 hormone\$).mp.
 57 exp Kinesiotherapy/ or physiotherapy/
 58 exercise.mp.
 59 exp Therapy/
 60 or/53-59
 61 52 and 60
 62 11 and 61

Appendix 3. The Cochrane Central Register of Controlled Trials (CENTRAL)

#1MeSH descriptor Mitochondrial Diseases explode all trees
 #2mitochondrial myopath*
 #3(mitochondrial encephalomyopath* or mitochondrial encephalopath*)
 #4(mitochondrial disease* or mitochondrial disorder*)
 #5(#1 OR #2 OR #3 OR #4)
 #6((CPEO or ophthalmoplegia) near5 progressive)
 #7cytochrome-c oxidase deficiency#8MeSH descriptor Electron Transport Complex III, this term only
 #9(Kearns near3 syndrome*)
 #10KSS
 #11(#6 OR #7 OR #8 OR #9 OR #10)
 #12((leber near5 neuropath*) or (Pearson near5 syndrome*) or (pearson near5 disease*))

 #13MeSH descriptor Optic Nerve, this term only
 #14MeSH descriptor Atrophy, this term only
 #15MeSH descriptor Optic Atrophy, this term only
 #16(#13 AND (#14 OR #15))
 #17LHON
 #18(MELAS near6 syndrome*)
 #19"lactic acidosis"
 #20MeSH descriptor Acidosis, Lactic, this term only
 #21(stroke near episode*)
 #22((#19 OR #20) AND #21)
 #23(#12 OR #16 OR #17 OR #18 OR #22)
 #24MERFF
 #25MIDD
 #26(maternal* near5 diabetes near5 deafness)
 #27(#24 OR #25 OR #26)
 #28((leigh syndrome*) or (leigh disease*))
 #29MNGIE
 #30 (mitochondrial neurogastrointestinal encephalomyopath*)
 #31(#28 OR #29 OR #30)
 #32retinitis pigmentosa
 #33MeSH descriptor Retinitis Pigmentosa, this term only
 #34MeSH descriptor Ataxia, this term only
 #35ATAXIA
 #36(#32 OR #33 OR #34 OR #35)
 #37NARP
 #38(pyruvate near5 carboxylase near5 deficiency near5 disease)
 #39pyruvate dehydrogenase complex deficiency disease
 #40(#36 OR #37 OR #38 OR #39)
 #41(#5 OR #11 OR #23 OR #27 OR #31 OR #36 OR #40)
 #42drug*
 #43MeSH descriptor Drug Therapy, this term only
 #44treatment
 #45MeSH descriptor Therapeutics, this term only
 #46 ("coenzyme Q10" or "co enzyme Q10" or carnitine* or creatine* or idebenone* or ubidecarenone* or "vitamin C" or "vitamin E" or menadione* or nicotinamide* or dichloracetate* or thiamine* or riboflavin* or succinate* or corticosteroid*)
 #47(growth near5 hormone*)
 #48exercise
 #49MeSH descriptor Exercise Therapy, this term only

#50diet*
 #51MeSH descriptor Diet Therapy, this term only
 #52(#42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50)
 #53(#41 AND #52)

WHAT'S NEW

Date	Event	Description
29 March 2011	New citation required but conclusions have not changed	G Pfeffer included among authors
29 March 2011	New search has been performed	New searches to July 2011. Six new studies included and two previously included studies now excluded, resulting in 10 included studies. Incorporated revised 'Risk of bias' methods

HISTORY

Protocol first published: Issue 4, 2003
 Review first published: Issue 1, 2006

Date	Event	Description
27 April 2008	Amended	Converted to new review format
12 September 2005	New citation required and conclusions have changed	Substantive amendment

CONTRIBUTIONS OF AUTHORS

For the first version of the review, all four authors agreed the criteria for inclusion of studies and their methodological quality. All four authors independently assessed all of the studies reviewed. PFC completed the first draft which was modified with comments from the other authors. GP and PFC updated the review. GP and PFC independently assessed all of the abstracts, including the original studies, to determine which required further review. All five reviewers agreed the criteria for inclusion of studies and their methodological quality. PFC modified the original review with GP, which was further modified following comments from the other reviewers.

DECLARATIONS OF INTEREST

Patrick Chinnery: none known.

Kari Majamaa: has received funding for travel from Octapharma and Lundbeck and speaker honoraria from OrionPharma.

Gerald Pfeffer: is the recipient of funding from the Clinician Investigator Program from the University of British Columbia in Vancouver, Canada, and a Bisby fellowship from the Canadian Institutes of Health Research. He reports no competing interests.

David Thorburn: none known.

Douglass Turnbull: our work was supported by The Wellcome Trust Centre for Mitochondrial Research (906919), the Newcastle University Centre for Brain Ageing and Vitality supported by BBSRC, EPSRC, ESRC and MRC as part of the cross-council Lifelong Health and Wellbeing Initiative (G0700718)

SOURCES OF SUPPORT

Internal sources

- No sources of support supplied

External sources

- Wellcome Trust, UK.
 - * Funding for PFC and DMT
- Muscular Dystrophy Campaign, UK.
 - * Funding for DRT
- Medical Research Council, UK.
 - * Funding for PFC and DMT
- Ataxia, UK.
- Association Francaise contre les myopathies, France.
 - * Funding for PFC and DMT
- Council for Health Research, Finland.
- Sigrid Juselius Foundation, Finland.
- Australian National Health and Medical Research Council, Australia.
 - * Funding for DRT
- Muscular Dystrophy Association, USA.
 - * Funding for DRT
- Parkinson's UK, UK.
 - * Funding for PFC and DMT
- National Institute for Health Research (NIHR), UK.
 - * Funding for PFC and DMT through the Newcastle NIHR Biomedical Research Centre in ageing and age-related disease
- Clinician Investigator Program, University of British Columbia, Canada.
 - * Funding for GP
- Canadian Institutes of Health Research, Canada.
 - * GP is in receipt of a Bisby Fellowship
- Juvenile Diabetes Research Foundation, Not specified.
 - * Funding for DRT
- Foundation for Children, Not specified.
 - * Funding for DRT

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

We removed the European Neuromuscular Centre (ENMC) clinical trials register from the resources to be searched.

For the 2012 update we incorporated 'Risk of bias' tables.

In the protocol we stated that all authors would review search results and select studies. For the update, two authors screened search results and selected studies for further review which were then assessed by all five authors.

For the update the study inclusion criteria were changed and the authors excluded quasi-randomised studies and studies at high risk of bias for any domain.

INDEX TERMS

Medical Subject Headings (MeSH)

Creatine [therapeutic use]; Dichloroacetic Acid [therapeutic use]; Mitochondrial Diseases [*drug therapy]; Randomized Controlled Trials as Topic; Sarcosine [analogs & derivatives] [therapeutic use]; Thioctic Acid [therapeutic use]; Ubiquinone [analogs & derivatives] [therapeutic use]

MeSH check words

Humans